Avi Biopharma Schweine/Vogel Virus mit staatlicher Unterstützung - 500 Beiträge pro Seite (Seite 2)

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.572.997 von eric949 am 14.07.09 22:30:32

wahsinn leute...schön wie sich unsere Avii-Perle wieder nach Norden klimmt!!

Bei der richtigen News sollte es demnächst direkt Richtung 2$ gehen!! Die Schweinegrippe ist nun auch wieder in den täglichen Medien sehr präsent...sie wird sich meines Erachtens noch viel viel größer verbreiten und dann wird unser Baby explodieren!!

[eric949]

Zur aktuellen Lage in England:

http://www.dailymail.co.uk/news/article-1199147/NHS-helpline…

NHS helplines swamped as swine flu panic rises after death of six-year-old girl

By Daniel Martin
Last updated at 9:45 AM on 15th July 2009

Swine flu helplines are being flooded with calls as panic over the deadly virus rises, it was revealed today.

Staff at NHS Direct have fielded more than 52,000 calls in the last week compared to a total of 190,000 since April.

Many of the callers are not thought to be ill but are scared because apparently healthy people have now started dying from the virus.
chris spencer director of education for hillingdon borough council speaks to the media

Chris Spencer, director of education for Hillingdon Borough Council, speaks to reporters outside St Catherine's Catholic School which Chloe attended

The rise in calls is despite health chiefs insisting there is no need to panic and trying to reassure people that measures to contain swine flu are in place.

Public fears have increased after yesterday's announcement that a healthy child and a GP with no known underlying problems have died from the virus.

The deaths of Chloe Buckley, six, and Dr Michael Day mean three people with no previous health problems have now died of the illness out of a total of 17 deaths across Britain.

Chloe's parents described her as their 'fun-loving baby girl' today as they spoke of their distress for the first time.

Health Secretary Andy Burnham said it was a 'tragedy' today but insisted people must not worry too much.

'There have been lots of children already having the condition but making a very quick and full recovery. We do have to keep it in perspective,' he said.

Britain was at the 'front of the queue' for the swine flu vaccine and the first should arrive here next month, the minister added.

'We could not be in a better position. So as soon as stocks are made, the very first vaccines will come to this country. We expect to get the first next month.'

Enough vaccine for the whole population has been ordered and half of all doses are expected to arrive by the end of the year.

A list has been drawn up of people who will get the first injections, including health workers and patients with conditions like diabetes and asthma.

Scientists fear a unique strain of the virus has already developed in London due to the sheer number of infections.

This could mutate into an even more virulent version which could prove more dangerous and faster-spreading.

However, experts are currently adamant swine flu is no more contagious than the normal seasonal flu and will prove mild for most who catch it.

'The vast majority of people will recover quickly by taking paracetamol or ibuprofen, and drinking plenty of fluids,' said Dr Laurence Buckman, chairman of the BMA's GP committee.

'We must remember that every year there are deaths from complications of seasonal flu; this is unfortunately inevitable with any strain of influenza.'

But the reassurances are falling on increasingly deaf ears as the death toll continues to rise.

A NHS Direct source told London's Evening Standard: 'Every day for the last week, more than half of all calls to NHS Direct have been in relation to swine flu and that is a huge increase from the start.

'It is to do with the deaths. When you read something about someone dying, people have more pressing questions. But the number of referrals to GPs have stayed pretty much the same so it shows people are simply more worried rather than ill.'

People are now being urged to use 'other channels' to release some of the pressure on the service, a spokesman added.

Schoolgirl Chloe died within 48 hours of complaining of a sore throat and just a day before her seventh birthday.

She was not given the anti-viral drug Tamiflu but her parents today insisted she had been treated appropriately.

Michael and Jacinta Buckley said in a statement: 'We are obviously very distressed at the loss of our fun-loving baby girl. Nothing can replace her in our lives.'

They added: 'We are satisfied that the medical care Chloe received at all times was appropriate.

It was also announced yesterday that Dr Day, a 64-year-old GP who had been treating swine flu victims, died after contracting the virus.

Both the little girl and the doctor are believed to have been perfectly healthy before succumbing to swine flu.
Dr Michael Day

Dr Michael Day died at the Luton & Dunstable Hospital on Saturday

Further tests are being carried out today to pinpoint an exact cause of death for Chloe and Dr Day.

The six-year-old, from West Drayton, West London, became ill on Wednesday and died on Thursday night.

Dr Day, a GP from Dunstable, Bedfordshire, died on Saturday in the Luton and Dunstable Hospital. He is also understood to have been healthy.

'Doctors have always accepted that there are risks associated with their job,' Dr Buckman said. 'Obviously these are smaller than they used to be with the advent of modern medicine, but they can never be eliminated altogether.

'It is understandable that people will be worried when they hear that a GP has died but we urge them to follow the recommended advice and contact their family doctor, rather than physically going to the surgery if they have symptoms.

'While these individual deaths are tragedies for the families concerned, it is very important that members of the public do not panic.'

Last Friday, the NHS announced the first case of a healthy person to have died of swine flu. All other deaths involved patients with underlying health problems.

The man, from Essex, who has not been named, fought for nine days before losing his battle against the virus.

[Massel]

im Bereich zu 1,60 und 1,70 US liegen anscheinend richtige Wiederstände... Wir brauchen mal ne schöne News um den Bereich hinter uns zu lassen...

Morgen Abend flieg ich für 2 Wochen in Urlaub und werde nun alle AVI HALTEN, drauf gepfiffen das dort keinen Zugriff aufs Internet habe. (bzw. das Labtop zu Hause lasse...)

Vielleicht gibt es ja ne schöne Überraschung wenn ich wieder da bin..

Poker & Eric, JUNGS; haltet brav die Stellung und merkt euch schonmal vor, dass massel über ALLE Vorkommnisse informiert werden will , wenn wieder da....

Ich bring euch auch ne schöne Überraschung mit, kann diese dann allerdings nur über BM mitteilen....

gruß
massel

[3ckv]

Antwort auf Beitrag Nr.: 37.582.275 von Massel am 16.07.09 07:11:41

einen schönen, erholsamen Urlaub.

[Massel]

Antwort auf Beitrag Nr.: 37.582.956 von 3ckv am 16.07.09 09:36:56

DANKE !!

gruß
massel

[eric949]

Alles klar Massel, wünsch Dir dann viel Spaß und gute Erholung!

Hoffe, Du kommst dann schön relaxed aus dem Urlaub zurück -
denn ich denke ab August wird sich so einiges tun...

Bin gespannt auf die Überraschung

All the best
Eric

[Massel]

In England geht die Post ab....



British swine flu cases rise by nearly 50% in a week

Row over conflicting advice to GPs and patients as latest figures set to be revealed

* Buzz up!
* Digg it

* Owen Bowcott
* guardian.co.uk, Thursday 16 July 2009 13.33 BST
* Article history

Fresh figures showing the rapid spread of swine flu across the UK will be released this afternoon as returns from GP surgeries show a rise of almost 50% in the last week.

The briefing from Sir Liam Donaldson, the government's chief medical officer, will provide updates on infection rates, numbers being treated in hospital and whether there have been more deaths.

Surveillance data from the Health Protection Agency will give a clearer picture of the progress of the pandemic. The death toll from the H1N1 virus stands at 16. The government is expected to announce the launch of a national swine flu helpline.

The flu is spreading fast across much of Britain and the total of those affected rose by 46% in the seven days up to last Sunday, according to data provided by family doctors.

Health ministers from across the UK – including those from Scotland, Wales and Northern Ireland – are now attending weekly meetings of the government's civil contingencies committee, Cobra, to assess the impact of the disease.

Information collected by the Royal College of General Practitioners' research and surveillance centre in Birmingham, which monitors communicable and respiratory disease, shows that the rate of people diagnosed with influenza-like illness in the north of England leapt from 6.6 per 100,000 of population from 29 June to 6 July to 37.2 per 100,000 between 6 and 16 July – almost a sixfold increase.

It more than doubled in central England from 42.8 to 93.9 per 100,000 but only rose slightly in the south from 72.1 to 74.9 per 100,000. However, cases in London – the swine flu "hotspot" along with the West Midlands – declined from about 180 to 140 per 100,000. Across England, the incidence increased from 50.3 to 73.42 during that week, a rise of 46%.

Professor Steve Field, the chairman of the Royal College, said: "Swine flu is spreading rapidly across the whole of the country now. GPs are saying that they are coming under a lot of pressure from patients who have it and many GPs say that the publicity surrounding the death of six-year-old London schoolgirl Chloe Buckley has increased demand and made people more anxious, although there is no reason for them to be so."

Children between five and 14 remain the worst affected, with an incidence rate of 160 per 100,000. The rate among under-fives is 114 per 100,000 and 89.4 among those aged 15-44.

The Royal College of GPs today complained that a submission it made to a House of Lords committee had been taken out of context. It insisted that it was "very pleased" with the responsiveness of health officials to the emergency. It had been asked to provide feedback from GPs about swine flu. Among one of the comments was that: "Family doctors also noted that conflicting advice was being provided by different agencies."

The NHS Direct website tells patients: "If swine flu is confirmed, ask a healthy friend or relative to visit your GP to pick up a document entitling you to antiviral medication." The statement raises the expectation that those diagnosed will automatically be given Tamiflu or Relenza to help reduce the flu's severity.

But advice circulated by the Royal College makes clear that even if a diagnosis is confirmed, clinical discretion means it may not be necessary to prescribe antiviral drugs to an infected but generally healthy patient. The advice given to GPs treating those diagnosed with swine flu who are not in a vulnerable medical category is to "consider authorisation of antivirals bearing in mind whether the patient has a strong preference for active treatment".

Field agreed that there appeared to be an "inconsistency" between the two lines of advice. "The last time [the advice] was changed was to give more discretion to GPs for dealing with those outside the at risk groups and partly to send the message to patients that they don't all need Tamiflu," he said.

The decision about whether to prescribe should be reached in "partnership" between doctor and patient, he said. "I don't think it's the GP's job not to give it."

The Department of Health said it did not believe there was any difference in the advice being proffered. "There's not going to be a case of people being refused Tamiflu," a spokeswoman said.

A GP who contacted the Guardian said the differing advice being given to GPs and patients was placing an unnecessary burden on GPs and out of hours care "resulting in hysteria and patients in real need being put at risk" because people were being told they needed Tamiflu "when they don't".

Gloucestershire police today defended the decision to send three officers wearing face masks, gloves and overalls into a house containing a suspected swine flu victim. "It was a precaution at the time but won't necessarily become standard practice," said a spokeswoman.

----------------------

gruß
massel

[eric949]

Hier die letzten News aus England, dort Headline bei allen
Tageszeitungen.

"Around 40,000 people a week in England and Wales are now complaining to their doctor of "flu-like illness", with a huge rise in the number of young children being affected."

http://www.telegraph.co.uk/health/swine-flu/5843700/British-…

[Massel]

Nix mehr mit den gewohnten Updates, die WHO stellt die bisherige kontinuierliche Berichterstattung mit den bisherigen Updates ein.
Anscheinend nimmt das Tempo der Infiktionen derartig zu, das die WHO
mit ihren Updates nicht mehr hinterher kommt !

Meine Meinung: Sollte der Virus zu einer gefährlichen Variante mutieren, stehen wir vor einer globalen Katastrophe !

---------------------------------------------------------

Pandemic (H1N1) 2009 briefing note 3
Changes in reporting requirements for pandemic (H1N1) 2009 virus infection

16 JULY 2009 | GENEVA -- As the 2009 pandemic evolves, the data needed for risk assessment, both within affected countries and at the global level, are also changing.

At this point, further spread of the pandemic, within affected countries and to new countries, is considered inevitable.

This assumption is fully backed by experience. The 2009 influenza pandemic has spread internationally with unprecedented speed. In past pandemics, influenza viruses have needed more than six months to spread as widely as the new H1N1 virus has spread in less than six weeks.

The increasing number of cases in many countries with sustained community transmission is making it extremely difficult, if not impossible, for countries to try and confirm them through laboratory testing. Moreover, the counting of individual cases is now no longer essential in such countries for monitoring either the level or nature of the risk posed by the pandemic virus or to guide implementation of the most appropriate response measures.
Monitoring still needed

This pandemic has been characterized, to date, by the mildness of symptoms in the overwhelming majority of patients, who usually recover, even without medical treatment, within a week of the onset of symptoms. However, there is still an ongoing need in all countries to closely monitor unusual events, such as clusters of cases of severe or fatal pandemic (H1N1) 2009 virus infection, clusters of respiratory illness requiring hospitalization, or unexplained or unusual clinical patterns associated with serious or fatal cases.

Other potential signals of change in the currently prevailing pattern include unexpected, unusual or notable changes in patterns of transmission. Signals to be vigilant for include spikes in rates of absenteeism from schools or workplaces, or a more severe disease pattern, as suggested by, for example, a surge in emergency department visits.

In general, indications that health services are having difficulty coping with cases mean that such systems are under stress but they may also be a signal of increasing cases or a more severe clinical picture.

A strategy that concentrates on the detection, laboratory confirmation and investigation of all cases, including those with mild illness, is extremely resource-intensive. In some countries, this strategy is absorbing most national laboratory and response capacity, leaving little capacity for the monitoring and investigation of severe cases and other exceptional events.
Regular updates on newly affected countries

For all of these reasons, WHO will no longer issue the global tables showing the numbers of confirmed cases for all countries. However, as part of continued efforts to document the global spread of the H1N1 pandemic, regular updates will be provided describing the situation in the newly affected countries. WHO will continue to request that these countries report the first confirmed cases and, as far as feasible, provide weekly aggregated case numbers and descriptive epidemiology of the early cases.

For countries already experiencing community-wide transmission, the focus of surveillance activities will shift to reporting against the established indicators for the monitoring of seasonal influenza activity. Those countries are no longer required to submit regular reports of individual laboratory-confirmed cases and deaths to WHO.

Monitoring the virological characteristics of the pandemic virus will be important throughout the pandemic and some countries have well-established laboratory-based surveillance systems in place already for seasonal influenza virus monitoring. Even in countries with limited laboratory capacity, WHO recommends that the initial virological assessment is followed by the testing of at least 10 samples per week in order to confirm that disease activity is due to the pandemic virus and to monitor changes in the virus that may be important for case management and vaccine development.

Updated WHO guidelines for global surveillance reflect in greater detail these recommended changes, in line with reporting requirements set out in the International Health Regulations.

RELATED LINKS
Interim WHO guidance for the surveillance of human infection with A(H1N1) virus
10 July 2009
--------------------------------------------

Ich denke, die WHO will einfach nur Panik vermeiden,
da bei veröffentlichung der Zahlen und der Schnelligkeit der
Verbreitung ohne weiteres ein wirtschaftlicher Kollaps drohen könnte...


gruß
massel

[eric949]

Alles klar Massel.

Klick mal meinen Link oben an.

In UK heute Headliner bei allen Tageszeitungen...
Wenn ich´s richtig verstanden habe, gibt es derzeit in UK
40.000 Neu-Infektionen pro Woche !!

Lies Dir den Artikel mal im Detail durch... die Situation in
England ist sehr extrem, es hat sich alles viel schneller aus-
gebreitet als befürchtet, das klingt extrem beängstigend !

Ist meiner Meinung nach kein Zufall, dass hier in den Medien
nicht über die Situation in England berichtet wird

Trotzdem schönen Urlaub

Eric

[Massel]

Antwort auf Beitrag Nr.: 37.589.483 von eric949 am 16.07.09 22:53:03

Danke, zum Glück gehts nicht nach England ,

gruß
massel

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.589.687 von Massel am 16.07.09 23:37:55

Schönen Urlaub Massel!!

Wo gehts denn hin??

Hab in einem Monat Urlaub und hab 2 Wochen Costa del Sol gebucht...hoffentlich zieht die Schweinegrippe dort vorbei!!

Freu mich schon auf deine Überraschung!!

Wir werden Avii bis dahin über die 2$ treiben, keine Angst!!

[Massel]

Hi Poker,

Danke....
rel. einsame Insel, auf die Malediven

probierts mal mir den 2,50 US,
dann bleibe ich 2 Wochen länger weg

gruß
massel

[Pokerlui007]

bei 2,50 geh ich direkt ins autohaus!!

[Pokerlui007]

bis jetzt schon ein nettes volumen (halbes vortagesvolumen) und es grüünt...steht da vlt. die nächste super news an!!??

http://www.nasdaq.com/aspx/nasdaqlastsale.aspx?symbol=AVII&s…

[Massel]

so , in 15 min klingelt der Abholer an der Haustür...

verabschiede mich bei RT 1,63 US von euch....

Bis Samstagabend in 2 Wochen....

legt mal ein "Dollarchen" drauf bis ich wieder da bin.


Gruß
massel

[donnerpower]

Am gleichen Tag wo ich den Thread zu AVI aufgemacht hatte..folgte vorher noch ein Thread zu BioCryst Pharmaceuticals...wie man sieht geduld zahlt sich aus, auch bei AVI werden wir bald Kurse über 2Dollar sehen !

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.594.278 von Massel am 17.07.09 15:46:46

MACHET JONG!!

[Pokerlui007]

SK 1,71$ wow!!

[Pokerlui007]

Moin Moin...auf eine grüne Woche und dass die 2$-Marke endlich fällt!!

Hier mal ein netter Link mit einer Übersicht zu allen Avii-News:

http://www.tickerspy.com/blog/?tag=avii

[revolt]

Antwort auf Beitrag Nr.: 37.594.299 von donnerpower am 17.07.09 15:49:18

haben die nun ein mittel, welches auch funktioniert?


grüße

[Pokerlui007]

Leeeeuuute hier ist Avii und nix ANDERES!!

sieht wieder schön grün aus heute...Sk 1,80$!?

[Pokerlui007]

hmm schade wieder leicht nach unten...Sk bei 1,68$!

Naja kann ja heute nur besser werden!!

[Pokerlui007]

ob als kurz oder lang-Investment...es sieht sehr bullish aus!!

http://www.stockta.com/cgi-bin/analysis.pl?symb=AVII&num1=1&…

[eric949]

Tut sich mal wieder gar nix heute...

Hoffe, die kommenden Tage geht´s up
Biocrsyt hat´s ja vorgemacht

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.615.987 von eric949 am 21.07.09 17:31:17

hier muss einfach die nächste news her...bin mir sicher da kommt noch was im juli, der war bis jetzt einfach viel zu ruhig!!

Wenn hier die nächste fette News kommt springen wir direkt über die 2$...aber nur meine bescheidene Meinung.

[eric949]

Antwort auf Beitrag Nr.: 37.619.617 von Pokerlui007 am 22.07.09 08:37:57

Seh ich genauso...

Wir bräuchten echt mal wieder ´ne ordentliche News...

Morgen steht ein FDA-Meeting zum Thema Flu Vaccine an -
mal sehen, was da bei rauskommt.

Schönen Abend

Eric

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.626.306 von eric949 am 22.07.09 20:57:34

servus eric!!

200k gehandelt in der letzten stunde und den kurs von 1,62 auf 1,73 anheben lassen...vlt. deutet das darauf hin dass viele vor morgen rein wollen in freudiger erwartung einer news auf der konferenz!!??

morgen wird ein schöner tag glaube ich!!

Schönen Abend noch!

[Pokerlui007]

Massel ist bestimmt stolz auf uns...

[donnerpower]

Antwort auf Beitrag Nr.: 37.626.939 von Pokerlui007 am 22.07.09 22:03:53

..aktuell laufen alle Bio Werte spekulativ wegen der Schweinegrippe..spätst. nächste Woche sehen wir hier 2Dollar wieder

[eric949]

Ja Massel wird unser Engagement hier sicher zu würdigen wissen

Bin schon gespannt auf seine Überraschung

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.627.561 von eric949 am 22.07.09 23:44:07

ohhh jaaa die steht ja auch noch aus!!

bin echt mal gespannt ob es heute ne schöne NEWS gibt...Zeit dafür wäre es!!!!!

[3ckv]

Antwort auf Beitrag Nr.: 37.628.339 von Pokerlui007 am 23.07.09 08:52:59

weiss jemand, was für eine Konferenz ansteht??


auf der Hompage finde ich nichts


Gruss

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.628.900 von 3ckv am 23.07.09 09:48:32

dieses hier:

http://www.fda.gov/AdvisoryCommittees/Calendar/ucm170908.htm

[eric949]

Bin mal gespannt, ob heute schon irgendwelche Ergebnisse des
FDA-Meetings bekannt werden.

Hier die neusten Infos aus Deutschland:

"Schweinegrippe in Deutschland:
Zahl der Infizierten steigt rasant

Die Schweingrippe breitet sich auch in Deutschland immer schneller aus: Von einem Tag auf den anderen ist die Zahl der neuen H1N1-Infektionen um 637 Fälle und damit um etwa ein Fünftel gestiegen, wie das Robert Koch-Institut mitteilte...."

http://www.stern.de/wissenschaft/mensch/:Schweinegrippe-Deut…

[eric949]

Die Lage in England spitzt sich zu...

100.000 neue Schweinegrippe-Fälle letzte Woche

Swine flu leaps to 100,000 suspects in a week
There have been an estimated 100,000 new cases of swine flu reported in England since last week and 840 patients are in hospital with the virus, 63 of them in intensive care, the Department of Health said...

http://www.independent.co.uk/life-style/health-and-families/…

[Pokerlui007]

direkt nach Börsenschluss sind gestern nochmal 40k zu 1,75$ über die Theke gegangen!!

Vielleicht kommt ja heute ne schöne News...

[Pokerlui007]

aus dem ihub:

Thomsan Reuters latest report (updated 7/22/09) rates AVII as a stong buy, 12 month price targets = Low $2.00, High $3.50, Mean $2.75

sounds good finde ich...

[Pokerlui007]

Leuuuute 1,84$ es geht LLLOOOOOOOOOOSSS!!!!!!

[Pokerlui007]

Zur Feier des Tages mal wieder ein real-time chart!

im Ami Board sehen alle heute schon die 2$-fallen!!

[3ckv]

Antwort auf Beitrag Nr.: 37.641.911 von Pokerlui007 am 24.07.09 16:14:24

wär ja mal was anderes, wenn ein WE grün würde.

auch NVAX etwa das selbe, nur bin ich dort nicht mehr drinn

[Pokerlui007]

1,93$ geil geil!!

bin jetz +130%

schade dass Massel dass nicht miterleben darf!!

[eric949]

Antwort auf Beitrag Nr.: 37.642.219 von Pokerlui007 am 24.07.09 16:47:32

Dann hat er wenigstens was, worüber er sich freuen kann, wenn er
wieder da ist

Und das ohne News, so muss es sein

Sieht heute aber bei den meisten Flu-Stocks ganz gut aus.
Denke mal, dass es an der allgemeinen Nachrichtenlage
liegt.

Wünsche schon mal ein schönes WE

[3ckv]

so, nun sind die 2$ aber fällig!

[donnerpower]

...es läuft, wie gesagt die 2Dollar werden wa nächste woche sehen

ps.

BIOCRYST jetzt auch fast zweistellig

[Macrocosmonaut [Blogger]]

Antwort auf Beitrag Nr.: 37.644.408 von donnerpower am 24.07.09 22:20:25

Avi ist inzwischen recht teuer - dafür das das Unternehmen weiterhin keine Profite abwirft und auf unabsehbare Zeit auch keine solchen abwerfen wird.

BCRX ist ebenso teuer - denn auch die werden keine Profite machen - und dafür ist der Wert ganz schön durch die Medien gepusht worden.

Interessanterweise findet man aber fast keine Pressekommentare zur Aktie von Biota - denn die hat wirklich das Zeug zu einer neuen Gilead...

Es ist schon interessant wie die Massen wieder genarrt werden...

Von der Pandemie werden nur eine Handvoll Unternehmen wirklich profitierten - der Rest wird am Ende wieder ins Nichts abtauchen und den Hype vielleicht dazu nutzen sich neues Geld an der Börse zu besorgen...

Gruss.

M.

Wie immer meine eigene Einschätzung und ohne Gewähr. Die gemachten Angaben stellen keine Handelsauffoderung dar. Aktien können steigen oder fallen. Jeder Investor handelt auf eigenes Risiko.

[donnerpower]

Antwort auf Beitrag Nr.: 37.645.493 von Macrocosmonaut am 25.07.09 11:36:35

Da mags du recht haben...ich habe auch bei beiden Bio Werten noch nie geschrieben das sie unterbewertet sind…es ist klar das solche Werte gerade durch die Medien mehr beeinflusst werden als ihre fundamentalen Daten…aber sieht ist halt Börse von heute aus.

gruss

[donnerpower]

Antwort auf Beitrag Nr.: 37.645.493 von Macrocosmonaut am 25.07.09 11:36:35

Wenn ich mir deine Biota anschaue...sehe ich nur das der Wert auch gerade in den letzten zwei Tagen über 100% hinter sich. So viel zu deinen Wert

[Pokerlui007]

Servus!

So letzte Woche ohne Massel...

Da wir am Freitag die 2$ Marke schon geknackt hatten, rechne ich heute bei US-Eröffnung fest damit dass wir diese direkt wieder überspringen werden. Es könnte gut sein, dass es diese Woche bis 2,5/3$ läuft, wenn sich die News und die rasante Ausbreitung noch weiter verschnellern!!

Ab 2,50$ werde ich mich dann ein wenig absichern, da ich jetzt schon bei über 100% bin...

Auf eine dunkel-grüne Avii Woche!!!!!!

[Pokerlui007]

sieht wieder gut aus heute...wenn jetzt noch ne News käme dann KNALLTS HIER RICHTIG!!!

http://www.nasdaq.com/aspx/nasdaqlastsale.aspx?symbol=AVII&s…

[eric949]

Antwort auf Beitrag Nr.: 37.653.143 von Pokerlui007 am 27.07.09 16:13:13

Poker, das dürfte weiter up gehen...
Bin zwar leider erst später eingestiegen als Du und kann mich
noch nicht über 120% freuen... aber besser als nix.

Denke, dass sich die allgemeine Nachrichtenlage weiter
zuspitzen dürfte, zumal vielen Regierungen nichts weiter
einfällt als den Leuten zu sagen, sie sollen sich mal
häufig die Hände waschen...

[MogD]

Antwort auf Beitrag Nr.: 37.653.331 von eric949 am 27.07.09 16:33:01

Wahnsinn 2,16$ !!!!

Zieeeehhhhhhhhhhh!!!!

[3ckv]

geht ja was


nur schade, das ich bei Nvax raus bin

aber was solls,

wenn hier die 3$ kommen, ist mir das Egal

[MogD]

Antwort auf Beitrag Nr.: 37.654.807 von 3ckv am 27.07.09 19:45:41

2,25$ haben wir schon mal.
Das Orderbuch sieht auch gut aus, bis 2,34$
liegt erstmal nichts im Weg

[eric949]

Und das Beste ist:

Ohne dass es irgendwelche AVI-News gäbe

Was soll dann erst passieren, wenn News kommen ?

[ambestenreichheiraten]

Antwort auf Beitrag Nr.: 37.654.807 von 3ckv am 27.07.09 19:45:41

Nvax hab ich noch allerdings hab ich mich bei Biocryst bei 4,25 Euro raustreiben lassen (akt. 7,70 Euro)

das wird mir hier nicht passieren....!

[donnerpower]

Biocryst und Avi heute wieder spitze...

[Pokerlui007]

moin moin leute!

ist ja schön dass auch hier langsam das interesse steigt!

Nach dem Sk Freitag auf 1,91$ nun das neue 52-Wochenhoch mit SK 2,10$ (nachbörslich sogar 2,15$).

Ich persönlich rechne fest damit dass hier in den nächsten Tagen ne fette News kommen wird und wir direkt Richtung 3$ ziehen werden!!

Ohhhhhhhhh wie ist das schööööööön, freue mich jeden Tag mehr über meinen EK bei 0,67€!!

Nur schade dass Massel nicht da ist, der wird AUGEN machen!!!

[Pokerlui007]

Nächster Widerstand erst bei 2,38$!

http://www.stockta.com/cgi-bin/analysis.pl?symb=AVII&num1=1&…

Denke dass es bei Intermediate vlt. heute oder morgen schon auf "very bullish" springen wird!

Im Ami-Board wird schon darüber spekuliert, dass Novartis wohl an Avii interessiert ist!!

[Pokerlui007]

könnte nachher ruck zuck Richtung 1,70€ bei uns gehen...

Rechne wieder mit einem hohen Volumen drüben, schon witzig wenn man bedenkt dass das Volumen bei uns seit Tagen quasi 0 ist und sich hier kein Schwein für die Aktie interessiert!!

[Pokerlui007]

NEWS!!!

AVI BioPharma and Action Duchenne Team Up to Support Advancement of PMO-Based Therapeutics for Treatment of Duchenne Muscular Dystrophy
Action Duchenne Provides $1.2m to Support Continuing Development of Drugs to Treat Duchenne Muscular Dystrophy

* Press Release
* Source: AVI BioPharma, Inc.
* On Tuesday July 28, 2009, 6:00 am EDT

*
Companies:
o Avi biopharma, inc.

CORVALLIS, OR and LONDON--(Marketwire - 07/28/09) - AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, and Action Duchenne, a leading UK charity dedicated to increasing awareness, engendering action and raising funds to find a cure for Duchenne Muscular Dystrophy (DMD), today announced a collaboration to support the acceleration of research and development for AVI's exon skipping candidate drugs for the treatment of DMD.

"AVI has a new class of candidate drugs which are an important contribution to Action Duchenne's search for a treatment for DMD. We have teamed up with AVI to help accelerate these clinical programs as part of our commitment to cure this devastating disease," said Nick Catlin, CEO of Action Duchenne. "Our primary goal is to help provide treatment options for the many children and adults afflicted with DMD. We believe we can provide significant value to AVI's ground breaking efforts."

"AVI and Action Duchenne share a common goal to advance new therapeutics and find treatment options for DMD patients," said Leslie Hudson, Ph.D., President and Chief Executive Officer of AVI BioPharma. "We believe this collaboration has high potential and we are also very pleased to receive the financial support from Action Duchenne which will help accelerate our research and development efforts for new exon skipping therapeutics."

The agreement has a one-year term, with an option to extend for additional years, and will provide approximately $1.2 million in support to AVI over the initial term for advancement of research, regulatory efforts and clinical trial recruitment.

AVI is currently conducting a dose-finding clinical trial evaluating the systemic delivery of AVI-4658. This is an open label, 12 week safety trial, which includes measures of drug efficacy and pharmacokinetics, being conducted in London, UK, at the UCL Institute of Child Health/Great Ormond Street Hospital NHS Trust facilities and at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK, which is the center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

AVI-4658 is designed to skip exon 51 of the dystrophin gene, allowing for restoration of the reading frame in the mRNA sequence. By skipping this exon, a truncated, yet potentially functional form of the dystrophin protein is produced, which could ameliorate the disease process and possibly prolong and improve the quality of life of these patients. Results from a Phase 1 proof-of-concept trial showed that injection of the drug into the muscles of a series of DMD boys successfully induced dystrophin production in a dose-responsive manner. Further, the drug was well tolerated, with no significant drug-related adverse events detected. The clinical trial was conducted in collaboration with the MDEX Consortium in London, UK. AVI is also developing AVI-5038, a new candidate drug based on second-generation PPMO chemistry and designed to skip exon 50. The preclinical work for AVI-5038 is funded in part by Charlie's Fund. The Company is currently working to advance this new drug candidate into clinical trials under an investigational new drug application (IND) in the United States and an investigational medicinal product dossier (IMPD) in Europe.

About Duchenne Muscular Dystrophy (DMD)

DMD is the most common fatal genetic disorder to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with Duchenne Muscular Dystrophy with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children before age six. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time in decades, there are promising therapies in or moving into development.

About Action Duchenne

Action Duchenne (formally Parent Project UK) was set up by Duchenne families in 2001 to promote new research for a cure for Duchenne. The charity has a strong record in funding research and has to date funded 9 major projects costing over �1m and has been a leading partner in the �1.6m DoH MDEX project. These projects have enabled much needed early work to be completed on exon skipping and other therapeutic approaches.

Action Duchenne holds an international conference every year to bring together researchers and families to exchange new research developments and provide a vital meeting venue for scientists.

In 2005 Action Duchenne launched the Duchenne Registry, the first National Duchenne database that holds gene information of people living with Duchenne and can be used to speed up the recruitment of patients for clinical trials. In 2006 Action Duchenne launched a comprehensive learning and behaviour toolkit for use by parents and education professionals. For more information please visit: www.actionduchenne.org

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

[dottore]

Duchenne Muscular Dystrophy
ist eine sehr seltene Erkrankung und wird wohl kaum einen Milliardenmarkt versprechen

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.659.753 von dottore am 28.07.09 13:17:14

trotzdem zeigt es mal wieder ganz klar, dass Avii sehr vielfältig tätig ist und nicht nur im Bereich der Schweinegrippe forscht!!

Hier entsteht bald ein global player!!

[Pokerlui007]

bid jetzt schon über 1,50€ bei uns!!

[Pokerlui007]

und wow sogar schon 6.600Stk Umsatz in Deutschland!!

[Pokerlui007]

Leuuuuutteeeeeeee ich habe gerade einen Teilverkauf zu 1,75€ gemacht....PLUS 158%!!!!!!

DANKE AVIIIIIIIIIIII!!!!!!!!

[Pokerlui007]

aktueller kurs bei 2,60$....noch keiner weiß was los ist, anscheinend steht die nächste News an!!

[Pokerlui007]

für gleich zum Live mitfiebern!!

http://www.nasdaq.com/aspx/nasdaqlastsale.aspx?symbol=AVII&s…

[3ckv]

Antwort auf Beitrag Nr.: 37.660.897 von Pokerlui007 am 28.07.09 15:16:26

Glückwunsch Pokerloui


Ich hoffe, ich kann die Avi Welle eine Weile mitreiten

[Pokerlui007]

ERIC, MASSEL heute kommt der Lohn unserer tapferen Arbeit in den letzten Monaten....heute ist Cash-Day!!!!!!

$$$$$$$$$

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.661.281 von 3ckv am 28.07.09 15:42:48

sei gegrüßt, danke! und selbst viel glück!

wenn wir heute noch die 2€ übersteigen, laufe ich nackt ums Haus!!

[3ckv]

Antwort auf Beitrag Nr.: 37.661.305 von Pokerlui007 am 28.07.09 15:44:31

aber mit Webcam

bist DU noch bei der X " Oma dabei?

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.661.491 von 3ckv am 28.07.09 15:56:26

nee xoma = oma....

nee spaß beiseite sehe dort kein potential bis jahresende 100%!!

[Pokerlui007]

wow volumen jetzt schon bei 3,6 Mio Shares, unfassbar!!

Kurs brökelt leicht, aber kein Wunder bei dem schnellen Anstieg vor ner Stunde! Teilverkauf bei 1,75€ hat sich bis jetzt bezahlt gemacht...

Sk bei 2,50$ wären ein Traum!!

[donnerpower]

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.663.115 von donnerpower am 28.07.09 18:23:33

5,5 Mio jetzt schon...die 10 Mio sind heute drin, das wäre glaube ich neuer Volumen-Rekord!!

[eric949]

Antwort auf Beitrag Nr.: 37.663.158 von Pokerlui007 am 28.07.09 18:29:12

Poker:
Ich bestehe drauf, dass Du dann wirklich nackt ums Haus läufst
und Beweisfotos postest

Schade, dass Massel das nicht miterleben kann - aber ich glaube
ehrlich gesagt, dass das noch nicht das Ende der Fahnenstange ist !

Der Anstieg kam ja ohne irgendeine fette AVI-News...
Überleg Dir mal was passieren könnte wenn wirklich mal ne
Hammer-News kommt

Der allgemeine Newsflow dürfte das Teil weiter beflügeln.

Wünsch Dir noch nen schönen Abend.
Meine anderen Babies (Sinovac etc.) entwickeln sich leider noch
etwas zäh.
Hoffe, da läuft es die Tage auch mal ähnlich.

[eric949]

PS:
Massel kann echt stolz auf uns sein.
Wir haben in seiner Abwesenheit hier ganze Arbeit geleistet

Hoffe, die Überraschung von ihm fällt dann auch ordentlich aus

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.665.739 von eric949 am 28.07.09 23:06:15

jaaaaaa die muss RIESIG für uns werden!!

Echt geil dass mein SK sogar bis auf 1Cent eingetreten ist...trotzdem habe ich mich einfach gestern mal mit einem Teilverkauf (leicht) abgesichert...die restlichen 4k lass ich bis 5$ laufen!!

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.665.715 von eric949 am 28.07.09 23:02:27

schreib mir mal ne PM mit deinen "sonstigen" Babies...bin neugierig!

[Pokerlui007]

Charttechnisch gibts erstmal keinen Widerstand nach oben!!

http://www.stockta.com/cgi-bin/analysis.pl?symb=AVII&num1=1&…

[Pokerlui007]

im ask sind schon die 2€ zu sehen...

[Pokerlui007]

NEWS

AVI BioPharma, Inc. to Present at IBC Drug Discovery & Development Conference: Oligonucleotide Therapeutics -- From Concept to Implementation

* Press Release
* Source: AVI BioPharma, Inc.
* On Wednesday July 29, 2009, 8:03 am EDT

*
Buzz up! 0
* Print

*
Companies:
o Avi biopharma, inc.

CORVALLIS, OR--(Marketwire - 07/29/09) - AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, today announced that it will present at the Oligonucleotide Therapeutics -- From Concept to Implementation Conference, part of IBC Life Science's Drug Discovery Development Week, taking place Aug. 3-5, 2009 in Boston, MA.
Related Quotes
Symbol Price Change
AVII 2.47 0.00
Chart for AVI BioPharma, Inc.
{"s" : "avii","k" : "c10,l10,p20,t10","o" : "","j" : ""}

Hong Moulton, Ph.D., Director of Discovery Research, is invited to present on Monday, Aug. 3. Her talk "Peptide-Mediated Muscle Delivery of Morpholino Oligomers for Treatment of Duchenne Muscular Dystrophy" will feature an overview of the Company's peptide-conjugated morpholino oligomer (PPMO) technology for treatment of this disease.

Duchenne muscular dystrophy (DMD) is caused by mutations in the human dystrophin gene. The potential utility of PPMO chemistry for the systemic treatment of DMD has been demonstrated in mouse and non-human primate models. Preclinical studies have shown that the PPMO conjugates entered muscle cells, caused targeted exon-skipping, restored dystrophin, and reduced pathology and improved function of muscles. Results from a single dose escalation clinical study of AVI-4658, a PMO therapeutic, demonstrate that a single intramuscular (IM) showed that injection of the drug into a small foot muscle of several DMD patients successfully induced dystrophin production in each patient as compared to placebo treated muscle in the contralateral foot.

Drug Discovery & Development Week in Boston, MA includes five targeted scientific conferences featuring strategies and forward-looking approaches to help attendees accelerate small molecules, antibody therapeutics and oligonucleotide therapeutics from early discovery to the clinic.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Contact:



AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
[phone]
[e-mail]

[3ckv]

hat da einer im Pr Markt

wirklich 1000stk zu 1.46 erhalten oder spinnt meine Anzeige??

alle anderen zu 2.5x ??????

[Pokerlui007]

UUUPPSS in Amiland hat sich Jemand beim verkaufen verdrückt bzw. die 2 mit der 1 vertauscht...der Käufer wird sich gefreut haben!!

08:18 $ 2.50 250
08:15 $ 2.54 400
08:15 $ 2.54 250
08:15 $ 2.54 100
08:15 $ 2.54 200
08:13 $ 2.53 400
08:12 $ 2.53 400
08:12 $ 2.53 1,800
08:12 $ 2.53 100
08:12 $ 2.53 1,700
08:12 $ 1.46 1,000
08:09 $ 2.53 100
08:09 $ 2.53 900
08:08 $ 2.53 500
08:05 $ 2.52 1,000
08:05 $ 2.51 200
08:05 $ 2.50 1,600
08:03 $ 2.58 100
08:03 $ 2.58 300
06:12 $ 2.66 800

[Pokerlui007]

wow wir sind im minus, das es so etwas auch nochmal gibt!!!

naja aber nur minimal und das volumen ist schon wieder riesig...denke dass wir spät. 17uhr die 2,50$ zurückerobert haben. bei dem kursanstieg in den letzten wochen sind ja gewinnmitnahmen nur menschlich und verständlich, hab ich ja gestern auch zum teil gemacht

[Pokerlui007]

moin!

schade dass es wieder ein wenig runter ging, aber ok nach der rally.

denke der kurs wird sich jetzt erstmal (bis zur nächsten news oder den zahlen) zwischen 2,20$-2,40$ einpendeln!

Auf 2 grüne Rest-Juli-Tage!!

[eric949]

Denke, dass es in der nächsten Zeit weiter up gehen könnte.

Die allgemeine Nachrichtenlage dürfte AVI weiter Auftrieb
geben und vielleicht kommt ja auch mal ´ne Hammer-News

[Pokerlui007]

Nächste nette News!!

VI BioPharma Moving Corporate Headquarters to Greater Seattle Area
Company Expands R&D Teams; Prepares for Commercialization by Outsourcing Drug Manufacturing; Focuses BioDefense Capabilities

* Press Release
* Source: AVI BioPharma, Inc.
* On Thursday July 30, 2009, 8:00 am EDT

*
Companies:
o Avi biopharma, inc.

CORVALLIS, OR--(Marketwire - 07/30/09) - AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, today announced the impending strategic move of its corporate headquarters and much of its leadership team to the greater Seattle area. The company plans to build upon and broaden its clinical development and drug discovery skill base by drawing upon the region's scientific expertise. The move will enable AVI to streamline its corporate operations and upgrade its capability to add new drug candidates to its pipeline in neuromuscular, immunological and viral diseases.

"AVI has reached a critical juncture in its evolution -- our pipeline of new and novel RNA-based therapeutics is growing and already has sparked significant interest and excitement from the scientific, pharmaceutical and financial communities. As we continue to develop our lead candidates towards potential regulatory approval, our ability to fully build out our organization and develop AVI's commercial capabilities will become a high priority," said Leslie Hudson, Ph.D., President and Chief Executive Officer of AVI BioPharma. "This move to the biotechnology hub in Seattle provides us with important competitive advantages in accessing experienced executives, scientists and regional collaborators. We look forward to being active and engaged corporate citizens in the region."

"The Puget Sound region is proud to be the home of approximately 200 life sciences organizations, as well as the host of world class universities, research institutes and prominent non-profit research organizations that together play an important and leading role in the global health community," said Chris Rivera, President of the Washington Biotechnology and Biomedical Association. "We are pleased and excited to welcome AVI -- a leading innovator in RNA therapeutics -- to the Washington biotechnology community. The company's move to our region is yet another example of the area's ability to attract top caliber talent and connect growing companies with the resources they need to thrive."

AVI has signed a lease agreement for a 19,000 square foot facility in Bothell, Washington that includes office and laboratory space. AVI expects to have operations underway in this new facility in August 2009, including the company's R&D efforts around its ongoing dose finding trial of AVI-4658 in patients with Duchenne muscular dystrophy (DMD). The company will relocate most of its leadership team to Seattle, relocate and recruit to its discovery teams in chemistry and biology, and also will add to its current teams in drug and business development.

AVI's Corvallis, Oregon laboratories will remain fully operational and will be dedicated to biodefense contracting and drug supply. AVI is developing novel antisense drug candidates for the treatment of a range of viruses, including H1N1 influenza, Ebola, Marburg and Jun�n viruses in collaboration with the US Army Medical Research Institute of Infectious Diseases (USAMRIID). This drug development effort is supported by several contracts from the Department of Defense's Transformational Medical Technologies Initiative (TMTI). Recently, AVI signed a contract with the U.S. Defense Threat Reduction Agency (DTRA) for the development of one or more nucleotide-based candidate drugs targeting the present pandemic of H1N1 swine flu.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

[Pokerlui007]

sooo die Amis geben schon wieder kräftig Gas nach der NEWS!!

2,53$!!!!

[Pokerlui007]

2,63$ und schon wieder über ne Mio Stück gehandelt (nach nicht mal 1 Stunde)...hier ist glaube ich was ganz großes im BUSCH!!

[3ckv]

2.69$

[MogD]

Antwort auf Beitrag Nr.: 37.679.443 von Pokerlui007 am 30.07.09 16:22:48

2,72$ neues Hoch und weiter steigend!
Da muß was Großes kommen!

Natürlich nur meine Meinung und keine Kaufempfehlung

[Pokerlui007]

ZIIIIEHHH!!!!!!!!

[Pokerlui007]

naja wird sich wohl heute zwischen 2,40 und 2,50$ einpendeln!!

bin morgen nicht online, also vertretet mich hier bitte entsprechend!!

[3ckv]

Antwort auf Beitrag Nr.: 37.681.208 von Pokerlui007 am 30.07.09 19:38:15

werd mir mühe geben

beim nächsten mal> 2.6 werfeich einige raus

[MogD]

Sieht ja erst mal gar nicht gut aus vorbörslich:
aktuell 2,15$

Warten wir mal ab, ob heute größere Gewinnmitnahmen
kommenn oder ob sich das Blatt noch mal wendet.

[Pokerlui007]

servus...bin ich einmal nicht da...

SK bei 1,30$ aber nachbörslich gings sogar bis auf 2,44$ wieder hoch!

denke wenn nächste Woche die nächsten News kommen, werden die 3$ anvisiert!!

Schönes Wochenende!!

[Massel]

Antwort auf Beitrag Nr.: 37.691.707 von Pokerlui007 am 01.08.09 08:55:17

Da iss man mal 2 Wochen weg und dann geht es richtig ab.....

Ich glaub ich fahr morgen direkt mal wieder, wie ich sehe
kann ich mich auf Euch verlassen...

Sieht schwer danach aus, das die Studienergebisse aus Phase 2 bald kommen und auch gut ausfallen, warum sollte man sich ansonsten
vergrößeren wollen und der Kurs so anziehen (Schweingrippe iss ja schon zu bekannt, bzw. eingepreisst) ??

Gibt es zu den Phase2 Ergebnisse schon Infos aus anderen Foren ?

gruß
massel

[eric949]

Hi Massel,

welcome back
Wie Du siehst, haben wir hier ganze Arbeit geleistet

Phase 2-Ergebnisse: Nicht das ich wüsste.

Nicht nur AVI ist angestiegen, auch Novavax, Biocr. und diverse
andere.
Hat m.E. weniger mit konkreten Firmen-News zu tun, sondern mehr
mit der allgemeinen Nachrichtenlage.

Mal sehen, was die Woche so bringt.

Gruß
Eric

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.694.467 von eric949 am 02.08.09 14:50:50

WELCOME BACK!!!!!!!

Freu mich schon auf deine Belohnung, wenns die noch gibt!?

Avii knackt diese Woche noch die 3$ denke ich...

[3ckv]

Antwort auf Beitrag Nr.: 37.694.003 von Massel am 02.08.09 11:56:21

hi Massel, Wilkommen

[Massel]

SOURCE: AVI BioPharma, Inc.

Aug 03, 2009 08:01 ETAVI BioPharma Announces Second Quarter 2009 Financial Results Conference Call
CORVALLIS, OR--(Marketwire - August 3, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, will hold a conference call to report second quarter 2009 financial results on Monday, August 10, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time).

Individuals interested in listening to the live conference call may do so by dialing 800-967-7135 toll free within the United States and Canada, or 719-457-2603 for international callers.

A replay of the call will be available by dialing 888-203-1112 toll free within the U.S. and Canada or 719-457-0820 for international callers. The passcode for the replay is 4026242. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

AVI Press and Investor Contact:
Julie Rathbun
Investor Relations
[phone]
[e-mail]

[Pokerlui007]

hmm tut sich wohl leider garnix heute bei uns...schade bei dem marktumfeld!!

naja dann muss ich wohl die nächsten tage mit nem dax-put meine gewinne machen!!

[Pokerlui007]

na toll massel wieder da und schon geht runter!!!!

wo bleibt denn nun die belohnung!?

[3ckv]

Antwort auf Beitrag Nr.: 37.705.663 von Pokerlui007 am 04.08.09 11:38:16

und schon gehts noch weiter runter

schade,schade

[Pokerlui007]

jo bin echt heilfroh über meinen teilverkauf bei 1,75€...meine restaktien bleiben jetzt liegen auch wenns nochmal runter geht.

auf long gesehen sollten hier locker 3-4$ drin sein!!

[ambestenreichheiraten]

...mal schaun.... die 2 Dollar könnten halten ....
Uptrend Chart ist auch noch intakt.... ich bleib dabei

[Pokerlui007]

tja man muss nur mal meckern....schon gehts von 2$ auf 2,14$ hoch!!

[Pokerlui007]

2,20$ Tageshoch!!

[ambestenreichheiraten]

Antwort auf Beitrag Nr.: 37.708.489 von Pokerlui007 am 04.08.09 16:41:13

tja man muss nur mal meckern...

Dann hau mal bitte so richtig auf den Putz !!!!!

[3ckv]

he he

2.26

kommt da noch was???

[3ckv]

da hat einer eine kleinere posi bei 2.26
zum verkauf eingestell

[3ckv]

der Weg bis knapp auf 2.40$ ist frei

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.709.578 von 3ckv am 04.08.09 18:47:05

dann mal rucki zucki männer....ZIIIIIEEEHHHH!!

[Pokerlui007]

so freunde mal sehn wo es heute hingeht...Richtung 2,40$ wäre schön!!

[Massel]

RT 2.33

PS: poker und eric , schreib euch bald ne BM (Überraschung)...

gruß
massel

[Massel]

uih.... RT 2.38 , da geht was heute

[3ckv]

Antwort auf Beitrag Nr.: 37.717.191 von Massel am 05.08.09 16:56:01

hoffen wir das die Dich erhöhren

[Massel]

Antwort auf Beitrag Nr.: 37.717.212 von 3ckv am 05.08.09 16:57:49

[Massel]

so, see you later, gegen 22 Uhr....., Pause ist überfällig..

[eric949]

Antwort auf Beitrag Nr.: 37.717.311 von Massel am 05.08.09 17:09:21

Hi Massel,

alles klar, bin gespannt auf die Überraschung

Was sagst Du zu Sinovac ?
Ich bin von dem Wert ja eigentlich überzeugt, hat Substanz
und die ersten Impfstoff-Tests sind positiv.
Aber alle anderen Stocks gehen ab, nur Sinovac nicht...

Mal sehen, ob da noch was geht

Gruß
Eric

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.717.768 von eric949 am 05.08.09 18:06:49

ja ich auch!! immer noch...

[Massel]

SK 2.35

eigentlich hätte ich nich gedacht das der Kurs heute solange nur seitswärts läuft..... aber unterm Strich mehr als zufrieden...
an der börse kommt meistens anderes als man denkt...

Sinovac... ich weiß nicht so recht was ich davon halten soll..
auf der einen Seite traue ich den Chinesen ne Menge zu, auf der anderen Seite lassen sich mit den Hühnereiern nicht soviele
Dosen produzieren....

Wie schätzt ihr die Zahlen am Montag bei AVI ein, eigentlich müssten die doch prima ausfallen bei den ganzen Aufträgen, oder ??

gruß
massel

[eric949]

Antwort auf Beitrag Nr.: 37.719.794 von Massel am 05.08.09 22:10:38

Denke mal, dass sie Zahlen ordentlich ausfallen werden.

Aber selbst wenn nicht, ist das m.E. bei der derzeitgen
Nachrichtenlage halb so wild.
Es geht jetzt eher um das Potenzial einer Firma in der
derzeitgen Pandemie.
Siehe Novavax, das was da gerade abgeht lässt sich mit
keinen Zahlen der Welt erklären

Sinovac bin ich am Überlegen, ob ich da nicht einen Teil
abziehe und umschichte. Mal schauen. Aber der Kursverlauf der
letzten Zeit war ales andere als ermutigend.
AVI, Novavax etc. haben sich alle verdoppelt.
Nur Sinovac nicht...

Gruß
Eric

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.720.262 von eric949 am 05.08.09 23:27:48

Zahlen werden gut ausfallen, das würde aber aktuell heißen dass der kurs fällt (das war bestimmt bei ca. 20 dax-unternehmen so)...aber egal!

Wenn wir Glück haben gehts im August über die 3$-Marke und danach ist mir eh alle egal!!

@Massel: Ich platze bald vor Vorfreude...spann uns nicht so laaaaaange auf die Folter!!!

[Massel]

Antwort auf Beitrag Nr.: 37.720.888 von Pokerlui007 am 06.08.09 08:22:35

keine Sorge, bis spätestens zum Wochende finde ich Zeit die BM
zu formulieren....

gruß
massel

[Pokerlui007]

so mal wieder ne News:

BioMed Realty Trust Commemorates Five-Year Anniversary as a Public Company
Ringing NYSE Closing Bell(R) Today; Provides Tenant Update

* Press Release
* Source: BioMed Realty Trust, Inc.
* On Thursday August 6, 2009, 6:00 am EDT

o
Buzz up! 0
o Print

*
Companies:
o AVI Biopharma, Inc.
o BioMed Realty Trust Inc.

SAN DIEGO, Aug. 6 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR - News), The Leading Provider of Real Estate to the Life Science Industry®, announced today that its board of directors and corporate officers will ring The Closing Bell® at the New York Stock Exchange on Thursday, August 6, 2009 at 4:00 p.m. Eastern Time to commemorate the fifth anniversary of the company's initial public offering. The ceremony will take place at the New York Stock Exchange, 11 Wall Street in New York City. BioMed's founders, Alan D. Gold, Chairman and Chief Executive Officer, and Gary A. Kreitzer, Executive Vice President, General Counsel and Director, will preside over the ringing of The Closing Bell®.
Related Quotes
Symbol Price Change
AVII 2.35 0.00
Chart for AVI BioPharma, Inc.
{"s" : "avii,bmr","k" : "c10,l10,p20,t10","o" : "","j" : ""}

"This is a great day for our team," said Mr. Gold. "Through their hard, smart work, our industry-leading team of professionals, now over 125 strong, has consistently produced results well beyond the initial expectations we had on that first day of trading in 2004, when we owned interests in just five properties, representing less than 400,000 square feet and generating less than $12 million in annualized base rents. Today, five years later, we have assembled the industry-leading portfolio of life science real estate, including 69 properties representing 10.5 million square feet and roughly $280 million in annualized base rents. While we are pleased with our progress to date, we are even more excited about the future for BioMed and the opportunity we see to create value for our shareholders, building on the strong foundation that we have established."

Mr. Gold further noted, "We are very encouraged by the significant volume of partnership transactions and capital raising we have observed in the life science industry over the last several months, particularly within our tenant portfolio. And while we remain very cautious with respect to the current leasing environment, the recent capital raising successes from our tenants serve as an indication that the primary mechanisms for funding the life science industry appear to be functioning effectively. In particular we note the continuing critical linkage between scientific advancements, capital raising and the leasing of space."

Mr. Gold continued, "It is noteworthy that these capital raising events extend across BioMed's tenant base. While research institutions, A-rated public companies and larger, established public companies comprise the vast majority - roughly 75% - of our tenant base, we are pleased to see healthy capital raising activity from our mid-stage and early-stage tenants as well."

One-half of BioMed's top ten tenants are research institutions or A-rated public companies, including Beth Israel Deaconess Medical Center, Children's Hospital Boston, Genzyme Corporation, Centocor, Inc. (a Johnson & Johnson subsidiary) and Schering Corporation. Each of BioMed's other top ten tenants publicly announced significant capital raising transactions in recent months:

* On August 3, 2009, Human Genome Sciences, Inc., the company's largest tenant, raised approximately $357 million in net proceeds from its common stock offering.
* On July 30, 2009, Vertex Pharmaceuticals Incorporated, the company's second largest tenant, announced that it will receive $105 million, in addition to potential milestone payments, from the sale of commercialization rights of telaprevir in Japan and other countries in the Far East to Mitsubishi Tanabe Pharma Corporation, after announcing its intention to sell certain future European milestone payments for telaprevir aggregating $250 million earlier in July and raising approximately $314 million in net proceeds from a common stock offering in February 2009.
* On July 23, 2009, Regeneron Pharmaceuticals, Inc., the company's fourth largest tenant, received a $20 million milestone payment from Bayer Healthcare for initiation of a Phase III clinical trial.
* On May 4, 2009, Ironwood Pharmaceuticals, Inc., the company's sixth largest tenant, entered into an agreement with Laboratorios Almirall, S.A. to license the European rights to develop and commercialize linaclotide, providing Ironwood pre-commercial licensing fees and milestone payments totaling $95 million, including a $40 million upfront licensing fee.
* On July 8, 2009, Arena Pharmaceuticals, Inc., the company's tenth largest tenant, raised approximately $50 million in net proceeds from a common stock offering. In addition, Arena entered into a $50 million equity financing commitment and a $100 million secured loan in recent months.

Many of BioMed's other tenants and their affiliated companies have also publicly announced significant financing transactions in 2009, some of which include:

* On May 27, 2009, Cephalon, Inc. raised approximately $288 million in net proceeds from a common stock offering and issued $500 million in convertible senior subordinated notes.
* On June 23, 2009, EpiCept Corporation raised approximately $9 million in net proceeds from a common stock and warrants offering, after raising approximately $25 million in gross proceeds from a public offering of convertible senior subordinated notes and warrants in February 2009.
* On February 19, 2009, InterMune, Inc. raised approximately $64 million in net proceeds from a common stock offering.
* On June 12, 2009, MDRNA, Inc. raised approximately $9 million in net proceeds from a common stock and warrants offering.
* On July 14, 2009, it was announced that sanofi-aventis, Novartis AG and MedImmune, a subsidiary of AstraZeneca PLC, would receive additional orders from the U.S. Department of Health and Human Services of $813 million for swine flu vaccine ingredients.
* On June 25, 2009, Merck & Co., Inc., the parent company of BioMed's tenant Aton Pharma, Inc., raised $4.25 billion from a public offering of senior unsecured notes.
* On June 9, 2009, NanoString® Technologies raised $30 million from a private equity financing.
* On April 1, 2009, Novavax Inc. raised approximately $10 million in net proceeds from the sale of common stock to a subsidiary of Cadila Pharmaceuticals as part of a new strategic alliance.
* On July 20, 2009, OncoGenex Pharmaceuticals, Inc. raised approximately $9 million in net proceeds from a direct common stock offering to certain institutional investors.
* On July 22, 2009, Profectus BioSciences, Inc. raised $5 million in a private equity financing.
* On July 7, 2009, Zosano Pharma, Inc. raised $30 million in a private equity financing.

In addition, the company announced the early retirement of approximately $44 million in mortgage notes secured by its Monte Villa Parkway (Bothell, Washington), Bayshore Boulevard (Brisbane, California) and 9885 Towne Centre Drive (San Diego, California) properties utilizing funds from the company's unsecured line of credit, which had a weighted average interest rate of 1.4% on the unhedged portion of the outstanding debt at June 30, 2009. As a result of this transaction, and following the company's success in securing a new $350 million mortgage financing for the Center for Life Science | Boston in June, BioMed has no remaining consolidated debt maturities for the balance of 2009 and 2010.

The company also announced today the signing of a new lease at its Monte Villa Parkway property with AVI BioPharma, Inc. (Nasdaq: AVII - News), a company focused on the discovery and development of RNA-based drugs. AVI BioPharma has agreed to lease approximately 19,000 square feet of laboratory and office space, which was previously leased to MDRNA, Inc. MDRNA continues to lease the remainder of the Monte Villa Parkway property, constituting approximately 32,000 square feet.

Kent Griffin, President and Chief Operating Officer of BioMed, commented, "The actions BioMed has taken over the course of several months at Monte Villa Parkway exemplify how we actively manage our portfolio and mitigate risk by working closely with our tenants, as well as prospective tenants, to understand their needs. In this case, we identified an opportunity and executed on a series of transactions that enabled us to transition underutilized space to a new tenant with attractive growth prospects and a strong capital position. We are very pleased to support AVI BioPharma's decision of relocating its headquarters to the Seattle area in order to streamline its corporate operations and upgrade its capability to add new drug candidates to its pipeline."

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry®. The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 114 buildings with approximately 10.5 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing, the use of debt to fund acquisitions and developments, and the ability to refinance indebtedness as it comes due; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

[Massel]

RT 2.26 ;

iss seit 2 Tagen immer so gewesen, ersten 1 bis 1,5 Std gedrückt und dann kammen die Käufe...

würde mich nicht wundern wenn es heute wieder so läuft....

gruß
massel

[3ckv]

ist ja mal ein ordentlicher brocken drinn bei 2.36

[Pokerlui007]

schöner schöner tagesverlauf....

montag gehts über die 3$ mit super zahlen!!

[Pokerlui007]

wow der kurs zieht ja schon schön an!!!

[Pokerlui007]

wow und es gibt sogar umsätze in deutschland..

denke mit guten zahlen und noch ein paar news diese woche sollte es über die 2€ gehen!!

[Massel]

Antwort auf Beitrag Nr.: 37.742.849 von Pokerlui007 am 10.08.09 10:51:30

um 13.30 GMT also Punkt 15.30 unserer zeit geht der conference call los.

gruß
massel

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.743.947 von Massel am 10.08.09 12:55:24

jo bin gespannt wie flitzebogen

[Pokerlui007]

BOTHELL, WA — Aug. 10, 2009 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today reported financial results for the three and six months ending June 30, 2009. The Company will host a conference call today, Monday, Aug. 10, at 9:30 a.m. Eastern time (6:30 a.m. Pacific) to review its financial results and corporate highlights (see below for details).



Revenues for the second quarter of 2009 were $2.9 million, compared to $5.0 million in the prior—year period, reflecting decreases in research contract revenues of $1.9 million. Revenues for the first half of 2009 were $6.1 million, compared to $10.6 million in the first half of 2008, reflecting decreases in research contract revenues of $4.5 million.



The net loss for the second quarter of 2009 was $19.7 million, or $(0.23) per share, compared with a net loss for the second quarter of 2008 of $1.8 million, or $(0.02) per share. The net loss for the second quarter of 2009 includes a non-cash expense for warrant liability of $14.6 million compared to a gain from the same source of $3.0 million during the second quarter of 2008. For the six months ended June 30, 2009, the Company reported a net loss of $20.6 million, or $(0.25) per share, compared with a net loss for the comparable period in 2008 of $16.8 million, or $(0.25) per share. The net loss for the six months ended June 30, 2009 includes a non-cash expense for warrant liability of $12.0 million compared to a gain of $1.6 million during the same period of 2008. The increase in warrant liability is a non-cash expense and is the result of the increase in the Company’s stock price subsequent to the issuance of the warrants as a part of the equity financing that closed in January 2009. The increase or decrease in the warrant liability fluctuates as the price of the Company’s stock fluctuates.



Research and development (R&D) expenses for the second quarter of 2009 decreased to $5.8 million from $7.7 million during the second quarter of 2008. R&D expenses for the first six months of 2009 decreased to $10.3 million from $14.6 million in the prior-year period. The decrease in R&D expenses for the second quarter and the six months of 2009 was due primarily to decreases in government research contracting costs associated with the decline in government research contract revenue. R&D expenses for the second quarter and the first six months also include higher expenses intended to accelerate the progress on AVI’s Duchenne muscular dystrophy projects.



General and adminstrative (G&A) expenses for the second quarter of 2009 were $2.2 million, unchanged from $2.2 million in the prior year’s second quarter. G&A expenses in the first six months of 2009 decreased to $4.4 million from $4.7 million in the prior-year period. The G&A expense decrease for the first six months was due primarily to stock compensation expenses incurred in the prior-year quarter related to the Ercole acquisition.




----------------------------------------------------- ---------------------------

[Pokerlui007]

klingt leider nicht so berauschend oder?

naja muss aber nicht zwansgläufig heißen dass es sich negativ auf den kurs auswirkt!!

[jambam1]

Hallo,

wo findet man denn die Kolumne von Bernecker ?

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.744.182 von jambam1 am 10.08.09 13:18:22

wat wo wie!???

[Pokerlui007]

ask bei uns schon von 1,77€ auf 1,55€ runter...hoffentlich kein schlechtes omen für gleich

[jambam1]

Antwort auf Beitrag Nr.: 37.744.269 von Pokerlui007 am 10.08.09 13:27:49

Entschuldige.

Seit der Umstellung (war bestimmt ganz wichtig ) ruckelt WO. Ist ja auch so schwer ein Forum zum Laufen zu bringen.

Deshalb bin ich jedenfalls im falschen Thread gelandet.

Aber ich glaube, ne Antwort krieg ich sowieso nicht.

[Massel]

Antwort auf Beitrag Nr.: 37.744.174 von Pokerlui007 am 10.08.09 13:17:46

auf Deutsch:

Ganz beschi......

so eine Mist, ich denke heute gibt es eine auf die Mütze,
nun aber verkaufen braucht man nun auch nicht mehr, da erfahrungsgemäß wahrsch. übertrieben geworfen wird und wir morgen und übermorgen bessere Kurse sehen werden....

No, No nach 0,01 Loss im Q.1 hätte ich mit 0,23 Loss im 2.Q nie gerechnet... so eine verdammte Hacke.....

gruß
massel

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.744.334 von Massel am 10.08.09 13:34:47

bin am überlegen...jetzt meine anderen auch noch verkaufen und später zu 1,30€ wieder rein oder so!?

[Massel]

Antwort auf Beitrag Nr.: 37.744.360 von Pokerlui007 am 10.08.09 13:37:22

Dein Ding.....

Meine hau ich zumindest am Anfang noch nicht raus.
tax ist jetz schon bei 1.43 Euro = 2.03 US = -20%

tiefer dürfte es eigentlich nicht mehr runter gehen,
will heißen die 2 US sollten halten...

Meine Hoffnung....

gruß
massel

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.744.405 von Massel am 10.08.09 13:41:26

ja haste auch wieder Recht...bin echt froh dass ich den Teilverkauf vor 2 Wochen bei 1,75€ realisiert habe!

Man sollte halt nicht so gierig sein....bin ich aber oft doch

[Massel]

Antwort auf Beitrag Nr.: 37.744.422 von Pokerlui007 am 10.08.09 13:44:13

eigentlich der richtige Tag um ggf. nachzulegen...

denn warum sollte AVI den sonst die neuen Räumlichkeiten gemietet haben, wenn da nix fettes unterwegs ist....

Nur bin leider voll in Biota drin

gruß
massel

[Pokerlui007]

ich denke auch dass die schlechten zahlen evtl. mit ner guten news (neuer vertrag) neutralisiert werden...

[Massel]

erster Pre-Market 2,10 US bei 3100 Volume.....

geht doch.....

[Pokerlui007]

erster kurs drüben: 2,10$...entspricht unserem aktuell ask von ca. 1,50€!

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.744.600 von Massel am 10.08.09 14:01:07

du hast noch ne offene frage von mir (per Bm)...

[Massel]

Antwort auf Beitrag Nr.: 37.744.609 von Pokerlui007 am 10.08.09 14:02:04

yep schon gesehen,
bitte mal die medikamente aus der Pipiline dazu....

[Pokerlui007]

2,40$ MASSEL!!!!!

[Massel]

pre wieder bei 2,40 US , bei kleinem Vol.;

massaker sieht anderes aus....

[Massel]

Antwort auf Beitrag Nr.: 37.744.663 von Pokerlui007 am 10.08.09 14:06:27

Buy on bad news....

[Pokerlui007]

AVI BioPharma Announces Second Quarter 2009 Financial Results & Corporate Highlights

* Press Release
* Source: AVI BioPharma, Inc.
* On Monday August 10, 2009, 8:00 am EDT

*
Companies:
o AVI Biopharma, Inc.

BOTHELL, WA--(Marketwire - 08/10/09) - AVI BioPharma, Inc. (NASDAQ:AVII - News), a developer of RNA-based drugs, today reported financial results for the three and six months ending June 30, 2009. The Company will host a conference call today, Monday, Aug. 10, at 9:30 a.m. Eastern time (6:30 a.m. Pacific) to review its financial results and corporate highlights (see below for details).

Revenues for the second quarter of 2009 were $2.9 million, compared to $5.0 million in the prior-year period, reflecting decreases in research contract revenues of $1.9 million. Revenues for the first half of 2009 were $6.1 million, compared to $10.6 million in the first half of 2008, reflecting decreases in research contract revenues of $4.5 million.

The net loss for the second quarter of 2009 was $19.7 million, or $(0.23) per share, compared with a net loss for the second quarter of 2008 of $1.8 million, or $(0.02) per share. The net loss for the second quarter of 2009 includes a non-cash expense for warrant liability of $14.6 million compared to a gain from the same source of $3.0 million during the second quarter of 2008. For the six months ended June 30, 2009, the Company reported a net loss of $20.6 million, or $(0.25) per share, compared with a net loss for the comparable period in 2008 of $16.8 million, or $(0.25) per share. The net loss for the six months ended June 30, 2009 includes a non-cash expense for warrant liability of $12.0 million compared to a gain of $1.6 million during the same period of 2008. The increase in warrant liability is a non-cash expense and is the result of the increase in the Company's stock price subsequent to the issuance of the warrants as a part of the equity financing that closed in January 2009. The increase or decrease in the warrant liability fluctuates as the price of the Company's stock fluctuates.

Research and development (R&D) expenses for the second quarter of 2009 decreased to $5.8 million from $7.7 million during the second quarter of 2008. R&D expenses for the first six months of 2009 decreased to $10.3 million from $14.6 million in the prior-year period. The decrease in R&D expenses for the second quarter and the six months of 2009 was due primarily to decreases in government research contracting costs associated with the decline in government research contract revenue. R&D expenses for the second quarter and the first six months also include higher expenses intended to accelerate the progress on AVI's Duchenne muscular dystrophy projects.

General and adminstrative (G&A) expenses for the second quarter of 2009 were $2.2 million, unchanged from $2.2 million in the prior year's second quarter. G&A expenses in the first six months of 2009 decreased to $4.4 million from $4.7 million in the prior-year period. The G&A expense decrease for the first six months was due primarily to stock compensation expenses incurred in the prior-year quarter related to the Ercole acquisition.

Net interest income declined primarily due to declines in market rates of interest on the Company's interest-earning investments.

AVI had cash, cash equivalents and short-term securities of $20.2 million as of June 30, 2009, an increase of $8.7 million from December 31, 2008. This increase was primarily due to the equity financing that raised net proceeds of $15.5 million, partially offset by cash used in operations of $6.0 million and property and equipment and patent-related costs of approximately $700,000.

"The first half of 2009 has been a period of sustained progress on several fronts for AVI, as we have secured a number of important new contracts and collaborations to support the advance of our promising development programs, including those for Duchenne muscular dystrophy," said Leslie Hudson, Ph.D., President and Chief Executive Officer. "We have established our claim as an innovator in the development of exon skipping technology, as well as, the development of antiviral therapeutics targeting H1N1 and potential biological threats such as Ebola, Marburg and Jun�n viruses."

Second Quarter and Recent Corporate Highlights

Duchenne Muscular Dystrophy

�
-- Entered into collaboration with Action Duchenne Limited, a leading UK
charity dedicated to increasing awareness, engendering action and raising
funds to find a cure for Duchenne muscular dystrophy (DMD), to support the
acceleration of research and development for AVI's exon skipping candidate
drugs for the treatment of DMD. The agreement has a one-year term, with an
option to extend for additional years, and will provide approximately $1.2
million in support to AVI over the initial term for advancement of
research, regulatory efforts and clinical trial recruitment.
-- Entered into an amended sponsored research agreement with Charley's
Fund Inc., a not for profit organization, to provide for an additional $3
million in sponsored research funds, for a total of $5 million in support
of the development of AVI-5038 for treatment of DMD through to IND.
-- Announced a $2.5 million contract with Children's National Medical
Center in Washington, D.C. to support preclinical studies in the
development of AVI-4658, for treatment of DMD. The collaboration will
support the series of GLP toxicology studies for AVI-4658 which is required
to release the clinical hold on the US IND.


BioDefense & Antivirals

�
-- Announced AVI is under contract with the U.S. Defense Threat Reduction
Agency (DTRA) for development of one or more nucleotide-based candidate
drugs targeting the present epidemic of H1N1 swine flu. The objective of
the contract, which includes a funding award up to $5.1 million, is to
accomplish the preclinical development of one or more medical
countermeasures based on AVI's proprietary antisense PMO backbone and
demonstrate efficacy using an appropriate animal model. Additional
information regarding the DTRA contract can be found at: www.fbo.gov (PDF).
-- Entered into an amendment to the contract with DTRA to support
additional tasks for the continued development of DTRA's programs with the
Transformational Medical Technologies Initiative ("TMTI") for the Company's
Ebola virus and Marburg virus therapeutic product candidates. Under this
amendment, DTRA has extended the contract performance period to
November 29, 2009 and added a cost modification of an additional $5.9
million, thus increasing the contract amount to $33.9 million.
-- Presented at the 7th Annual Biodefense Vaccines & Therapeutics
conference taking place in Washington, D.C. as part of a pre-conference
symposium on "Developments in Biodefense Technology Platform." As an
invited participant in the session titled "Building Technology Platforms to
Array Against Multiple Threats," Dr. Patrick Iversen discussed the utility
of AVI's RNA-based drugs against biological threats, including Ebola and
Marburg viruses.
-- Presented preclinical findings using an antiviral oligomer compound
that incorporates AVI's proprietary backbone chemistry (PMOplus(TM)) at the
American Society of Virology Annual Meeting.
-- Received key patents for drug candidate AVI-6002 targeting Ebola Zaire
Virus protein VP35.The patents cover composition and methods to target the
Ebola virus VP35 protein with a range of PMOplus(TM) compounds.


Corporate

�
-- Announced the move of its corporate headquarters and much of its
leadership team to the greater Seattle area.
-- Appointed Paul Medeiros, Senior Vice President of Business Development
and Chief Business Officer. Medeiros most recently served as Vice
President, Global Licensing and Strategic Alliances for Schering-Plough,
where he led worldwide specialty product licensing and strategic partnering
initiatives.
-- Announced that AVI joined the broad-market Russell 3000� Index
following Russell Investments' annual reconstitution of its comprehensive
set of U.S. and global equity indexes. Membership in the Russell 3000,
which remains in place for one year, means automatic inclusion in the large-
cap Russell 1000 Index or small-cap Russell 2000 Index as well as the
appropriate growth and value style indexes.


Guidance:

For 2009, AVI confirms its guidance for expenditures for operations, net of government funding and other collaborative efforts, to be approximately $10 to $12 million. The Company believes it will receive additional funding from government and other sources to pursue the development of product candidates, and has assumed certain revenues from these awards in providing this guidance. If the Company does not receive the additional contracts or if their award is delayed, this might have a negative impact on this guidance.

Conference Call

AVI management will hold a conference call to report second quarter 2009 financial results on Monday, August 10, 2009, at 9:30 a.m. Eastern time (6:30 a.m. Pacific time). Individuals interested in listening to the live conference call may do so by dialing 800-967-7135 toll free within the United States and Canada, or 719-457-2603 for international callers.

A replay of the call will be available by dialing 888-203-1112 toll free within the U.S. and Canada or 719-457-0820 for international callers. The passcode for the replay is 4026242. In addition, a recording of the call will be available within approximately 24 hours at www.avibio.com.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

�
AVI BIOPHARMA, INC.
(A Development-Stage Company)
(unaudited)
(in thousands)


Three Months Ended Six Months Ended
June 30, June 30,
---------------------- ----------------------
2009 2008 2009 2008
---------- ---------- ---------- ----------
Revenues, from license
fees, grants and research
contracts $ 2,945 $ 4,983 $ 6,095 $ 10,608

Operating expenses:
Research and development 5,804 7,678 10,299 14,581
General and
administrative 2,206 2,184 4,426 4,737
Acquired in-process - - - -
Research and
development - - - 9,916
---------- ---------- ---------- ----------
8,010 9,862 14,725 29,234

Other income (loss):
Interest (expense)
income and other, net (31) 81 (15) 248
(Increase) decrease on
warrant liability (14,572) 3,047 (11,950) 1,613
---------- ---------- ---------- ----------

Net loss $ (19,668) $ (1,751) $ (20,595) $ (16,765)
========== ========== ========== ==========
Net loss per share--
basic and diluted $ (0.23) $ (0.02) $ (0.25) $ (0.25)
========== ========== ========== ==========
Shares used in per share
calculations 85,664 70,986 83,235 68,154
========== ========== ========== ==========



BALANCE SHEET HIGHLIGHTS
(unaudited)
(in thousands)

June 30, December 31,
2009 2008
---------- -----------
Cash, cash equivalents and short-term
securities $ 20,205 $ 11,474
Total current assets 24,329 17,044
Total assets 32,617 25,536
Total current liabilities 26,288 7,288
Total shareholders' equity $ 3,788 $ 15,732

[Pokerlui007]

so von 2,10 auf 2,25$...sieht schon wieder besser aus!!

Denke dass wir bei 2,40$ stoppen könnten, dann hätten wir die News echt gut verdaut!!

[Massel]

Antwort auf Beitrag Nr.: 37.745.081 von Pokerlui007 am 10.08.09 14:51:12

ja und wenn am ehrlich an die Sache rangeht wurden die Einnahmen von AVI ja stets gemeldet, eigentlich konnte man nachrechnen....

Nach einem Abverkauf sieht es def. nicht aus.
, sonst hätte es im Pre vielmehr gerummst....

[Pokerlui007]

nein kein abverkauf...scheint schon verdaut Massel!!

2,31$ aktuell

[Pokerlui007]

cool schon PLATZ 30!!

[Massel]

ask bid in FRA schon wieder bei 1,57 zu 1,67 ...

[Massel]

RT 2.30 US

[Pokerlui007]

es wird, es wird!!

denke hier kommt heute vlt. noch ne NEWS nach dem call...ansonsten wären wir schon 2-stellig im Minus!

Hier ist was im Busch...

[eric949]

Antwort auf Beitrag Nr.: 37.745.516 von Massel am 10.08.09 15:31:14

Sieht trotz der Zahlen ja ganz ordentlich aus.

Hatte ja schon mal angemerkt, dass Zahlen bei Novavax, Avi etc.
zur Zeit m.E. nicht die grosse Rolle spielen.
Zum Glück

[Massel]

RT 2.32 US, wenn wir heute im Plus schließen muß ne Flasche Rama dran glauben

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.745.696 von Massel am 10.08.09 15:44:22

2,23$...

ab jetzt 2 Flaschen Rama!!

[Massel]

schwupp di wupp kartoffelsupp
sind wir wieder bei

RT 2,30 US

merkwürdig, merkwürdig....

[Massel]

RT 2.34 US

[3ckv]

na dan hoffen wir doch mal, das hier noch was geht

[Pokerlui007]

hmm wohl doch nicht...SK 2,18$ tippe ich

[Massel]

hätte schlimmer ausgehen können, unterm Strich bin ich zufrieden....
kann innerhalb von 1 Tag wiederaufgeholt werden....

gruß
massel

[Massel]

iss ja eigentlich nur der Anstieg vom freitag genommen worden...

After Hours Trade Reporting
Pre-Market Charts | After Hours Charts
After Hours
Last: $ 2.22 After Hours
High: $ 2.2331
After Hours
Volume: 9,800 After Hours
Low: $ 2.20

[Pokerlui007]

Hallo zusammen!!

Ich habe gerade meine letzten 4000stück veräußert (auch mit ein wenig schweren herzens). Ich denk bei Avii ist vorläufig erstmal ein wenig die Luft raus...ich bin jetzt bei Biota und Cell Therap. drin!

Danke schonmal vor allem an Massel und Eric an die tolle Zusammenarbeit!! Ich werde trotzdem weiter hier rein schauen und auch mitlesen...wir bleiben hoffentlich weiter in Kontakt und sehen uns bei anderen Biopharma Werten wieder!

Danke auch nochmal an Avii an über 100% Gewinnsteigerung in 3 Monaten...

Gruß
Lui

[3ckv]

viel Glück Pokerloui

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.754.199 von 3ckv am 11.08.09 14:47:27

danke dir auch!!

Bis bald mal...

[Rainbowfu]

Wenn ich sehe, wieviele in AVI investiert haben und sind und sehe dann das mögliche Potential, dann betrachte ich diese Kurse (bei dem genannten Verlust) als sehr niedrig. Ich bin gut investiert und überlege, ob ich nachlege. Kaum vorstellbar, dass es unter 2$ geht... dafür sind die Möglichkeit zu groß....und die Erkrankungen, Virenerkrankungen zu gewaltig...

[Massel]

Antwort auf Beitrag Nr.: 37.762.398 von Rainbowfu am 12.08.09 13:25:21

wer die Wahl hat , hat die Qual, AVI ist sicher eine Perle,
heisst aber nicht das es nicht noch schönere gibt....

Ich bleib vorerst drinn....

[Rainbowfu]

wer a sagt, sollte auch b sagen, aber bitte komme nicht mit Genta, washington mut, eher schon mit Nabi Bio

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.762.845 von Rainbowfu am 12.08.09 14:12:28

Avanir Therap.

Biota

Cell Therap.


nur als kleiner Tipp von mir...

[Pokerlui007]

ich hoffe und bete mit Euch dass die 2$ Marke hält!!

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.773.778 von Pokerlui007 am 13.08.09 15:44:34

hmm schade für euch...aktuell bei 1,80$ aber das wird schon wieder!!

drück Euch die Daumen!!

[Massel]

Antwort auf Beitrag Nr.: 37.784.543 von Pokerlui007 am 14.08.09 17:12:41

Wer gewinnt muß auch einstecken können....
Der Verfall wäre eigentlich Nach Q2-Zahlen eher erklärbar gewesen,
daher wirds wahrscheinlich schnell wieder über 2 US gehen.

gruß
massel

[MogD]

Antwort auf Beitrag Nr.: 37.786.861 von Massel am 14.08.09 22:43:44

Das was dann erst mal mit 2$ - bleibt eher die
Frage ob 1$ gehalten werden kann:

Quelle:
http://www.finanznachrichten.de/ext/goto.asp?id=14739091


AVI BioPharma Announces Pricing of Public Offering of Common Stock and Warrants

BOTHELL, WA--(Marketwire - August 20, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII) today announced the pricing of the public offering of 21,126,761 shares of common stock and warrants to purchase an additional 8,450,704 shares of common stock at a price to the public of $1.42 per unit. Each unit consists of one share of common stock and a warrant to purchase 0.40 of a share of common stock. The shares of common stock and warrants are immediately separable and will be issued separately. The warrants have an exercise price of $1.78 per share of common stock, have a term of five years, and are exercisable starting with the date that is six months from the date of the closing of the offering. In addition, AVI BioPharma has granted the underwriters a 30-day option to purchase up to an additional 3,169,014 units, consisting of 3,169,014 shares of common stock and warrants to purchase 1,267,606 shares of common stock, to cover over-allotments, if any.

Jefferies & Company, Inc. is acting as sole book-running manager in this offering. The co-manager in this offering is JMP Securities LLC.

AVI BioPharma expects the offering to close on or about August 25, 2009, subject to customary closing conditions. Assuming no exercise of the underwriters' over-allotment option, AVI BioPharma expects to receive gross proceeds from the offering of approximately $30 million.

The offering is being made only by means of a prospectus and related prospectus supplement, copies of which may be obtained from Jefferies & Company, Inc., Attention: Syndicate Prospectus Department, 520 Madison Avenue, New York, NY, 10022 or at [phone]. Electronic copies of the prospectus and the prospectus supplement are available on AVI BioPharma's website at www.avibio.com.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of the securities, nor shall there be any sale of these securities in any state in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities law of such state.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action.

Forward-Looking Statements Safe Harbor. This press release contains forward-looking statements regarding our plans, expectations, estimates and beliefs. Such statements are "forward-looking statements" for purposes of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. Our actual results could differ materially from those discussed in, or implied by, these forward-looking statements. Forward-looking statements are identified by words such as "believe," "anticipate," "expect," "intend," "plan," "will," "may," and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements are based on current expectations and are not guarantees of future performance. We caution you not to place undue reliance on these statements, which speak only as of the date on which the statement was made. Forward-looking statements in this press release include, but are not necessarily limited to, those relating to the expected closing date of the offering, the expected proceeds and expenses and the expected use of funds from the offering. Forward-looking statements are subject to risks and uncertainties, certain of which are beyond our control. Actual results could differ materially from those anticipated as a result of the factors described in "Risk Factors" in AVI BioPharma's periodic reports filed from time to time with the Securities and Exchange Commission. Given these uncertainties, undue reliance should not be placed on these forward-looking statements. AVI BioPharma does not undertake any obligation to release any revisions to these forward-looking statements publicly to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

[Massel]

ja, das stimmt...

so kann halt Börse auch sein...

gruß
massel

Biota (WKN 887853)Ende 2009:Cash-Sonderzahlung von 0,11 AUD je Share http://www.biota.com.au/uploa/154/1021551_26lettertosharehol…

[borsaci32]

weis einer wieso der kurs so steigt oder ist der kursrutsch gestoppt

[MogD]

Antwort auf Beitrag Nr.: 37.853.663 von borsaci32 am 26.08.09 11:12:43

Ich schätze mal deswegen:

Quelle: http://www.marketwire.com/press-release/Avi-Biopharma-Inc-NA…



AVI BioPharma Phase 1 Proof of Concept and Safety Data for AVI-4658 in Duchenne Muscular Dystrophy Featured in Lancet Neurology

AVI-4658 Demonstrates Compelling Proof of Concept and Safety Profile for Pediatric Patients With DMD; Findings Support Progression to Current Systemic Use Trial

BOTHELL, WA--(Marketwire - August 25, 2009) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that the results and scientific findings of its Phase 1 clinical trial assessing the "proof of concept" and safety of AVI-4658 in patients with Duchenne Muscular Dystrophy (DMD) have been published online in the journal, Lancet Neurology. DMD is an incurable muscle-wasting disease associated with errors in the gene that makes dystrophin. These findings, which show that treatment with AVI-4658 was safe and effective in inducing dystrophin expression, suggest that AVI-4658 could have promise as a drug for the treatment of DMD. The paper will be published in the October print issue of the journal.

The paper, "Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study," was authored by AVI and a group of preeminent DMD researchers including Professor Francesco Muntoni, the principal investigator of the UK MDEX Consortium. The publication was featured in the journal along with commentary and review from scientists at the Leiden University Medical Center. This external review explored AVI's data in comparison to similar recent antisense technology findings, with an alternative chemistry, and ultimately underscored the overall therapeutic potential of antisense technology in this indication and, importantly, the need for a safe antisense therapy that could be dosed at effective levels for lifelong use in pediatric patients living with DMD.

"We are extremely excited by these promising data for AVI-4658 in patients with DMD, which further validate the excellent safety of our extensively studied core chemistry around phosphorodiamidate morpholino oligomers, or PMOs," said Dr. Stephen B. Shrewsbury, Chief Medical Officer and Senior Vice President of Preclinical, Clinical and Regulatory Affairs of AVI. "We believe that these data and our additional findings to be presented at the upcoming 14th Annual International Congress of the World Muscle Society will provide the DMD community with the opportunity to fully understand the promising safety and efficacy of the PMO therapies being developed for chronic, lifelong use in children living with DMD."

The Lancet Neurology publication details AVI's Phase 1 study, in which Professor Muntoni and his team conducted a single blind, placebo-controlled, dose escalation study in DMD patients to assess the safety and proof of concept of a single intramuscular administration of AVI-4658 into a small foot muscle -- the extensor digitorum brevis (EDB). Biopsies of placebo and drug-treated muscles from each patient were conducted approximately three to four weeks following this intramuscular injection. The primary endpoint of the trial was to determine safety and tolerability, especially in terms of the potential for an immune response to newly expressed dystrophin induced by the ability of AVI-4658 to skip exon 51 and so enable protein expression. The findings of the study show that there were no drug related serious adverse events in the study, no adverse event signal related to the administration of study drug AVI-4658 and no observed immune response to the newly expressed dystrophin. This PMO therapy induced detectable exon skipping at a very low drug dose of 0.09 mg and at the 0.9 mg dose the skipping of exon 51 led to high levels of dystrophin expression, compared to the placebo-treated muscle on the other foot. It is important to note that the dystrophin levels achieved per cell -- up to 42 percent of those found in healthy muscle -- exceeded the levels reported from a recent 2'O-Methyl-oligonucleotide (2'O-Me) DMD clinical trial referenced in the external review by the Leiden University Medical College researchers.

"The growing body of promising data for potential treatments for DMD is a significant milestone in and of itself and one that we are extremely encouraged to see realized," said Nick Catlin, Chief Executive Officer of Action Duchenne, a leading UK charity dedicated to increasing awareness, engendering action and raising funds to find a cure for DMD. "Action Duchenne believes that these results from AVI are promising and we are excited to be working with the company and supporting its research through Action Duchenne funding. We are pleased that DMD patients and their families are beginning to see long-awaited movement toward a potential safe, well tolerated and effective therapy for this devastating disease."

AVI also announced today that it will present these Phase 1 data at the 14th International Congress of the World Muscle Society, along with late-breaking, preliminary data from its currently ongoing Phase 1b/2 clinical trial evaluating the systemic administration of AVI-4658 in boys with DMD. These preliminary findings from the ongoing trial continue to confirm the excellent safety record of PMO therapy, validate AVI's novel approach to treating DMD with this PMO class and show that AVI-4658 has been very well tolerated by DMD patients in the first two completed dosing cohorts in the trial. There have been no serious adverse events or drug-related adverse events identified and the independent Data Safety Monitoring Board has approved each of the AVI trial's dose escalations. Dosing at 4mg/kg is ongoing. In the coming weeks, AVI expects to escalate to two higher doses -- 10 and 20 mg/kg -- which, at 12 weeks duration, will exceed both the dose levels and the duration of dosing previously studied elsewhere with the alternative 2'O-Me approach. AVI believes that this encouraging and growing safety profile, duration of exposure and approved dose escalations are extremely important clinical advances for its PMO chemistry approach as any dose-limiting toxicity, especially after only short-term exposure, could severely limit the effectiveness of a DMD therapy in this chronic condition where treatment must continue for life.

"These data are both important and timely and we at AVI believe that we could be at a critical juncture in the treatment of this debilitating and fatal disease," said Dr. Leslie Hudson, President and Chief Executive Officer of AVI. "We are pleased to have the support of Action Duchenne and other research and patient organizations that are committed to accelerating the development of safe and effective drugs for DMD patients. Further, we are eager to continue our work with our clinical collaborators and the U.S. and European regulatory authorities as we work to develop AVI-4658 -- which has both orphan drug and fast track status -- as safely and expeditiously as possible."

The currently ongoing Phase 1b/2 dose-finding clinical trial is evaluating the systemic delivery of AVI-4658. This is an open label, 12-week safety trial, which includes measures of drug efficacy and pharmacokinetics and is being conducted in London, UK at the UCL Institute of Child Health / Great Ormond Street Hospital NHS Trust facilities and at the Royal Victoria Infirmary, Newcastle-Upon-Tyne, UK which is the coordinating center for the European Treat Neuromuscular Diseases (Treat-NMD) initiative. The clinical costs for the trial are provided, in part, by the UK Medical Research Council.

About Duchenne Muscular Dystrophy (DMD)

DMD is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with Duchenne Muscular Dystrophy with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing, requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into clinical development.

About the MDEX Consortium

The MDEX consortium led by Professor Francesco Muntoni, is a multidisciplinary enterprise to promote translational research into muscular dystrophies, and is formed by the clinical groups of Professor Francesco Muntoni (UCL Institute of Child Health) and Professor Kate Bushby and Professor Volker Straub (Newcastle University), and scientists from Imperial College London (Professor Dominic Wells), UCL Institute of Child Health (Dr. Jennifer Morgan), Royal Holloway University of London (Professor George Dickson), Oxford University (Dr. Matthew Wood) and University of Western Australia (Professor Steve Wilton). In addition, the charities Muscular Dystrophy Campaign (MDC), Action Duchenne and Duchenne Family Support Group also participate in the Consortium. For more information, visit www.mdex.org.uk.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.

[Pokerlui007]

komme bald wieder an bord denke ich...

[donnerpower]

Antwort auf Beitrag Nr.: 37.879.063 von Pokerlui007 am 29.08.09 16:33:55

...zu spät

[dw1z]

genau so! laaaauf avi =)

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.898.233 von donnerpower am 01.09.09 22:32:41

ja leider dieses mal wirklich!

egal warte auf evtl. rücksetzer....will wie beim 1. mal unten rein und oben raus!

Order zu 1,20€ ist drin

[Pokerlui007]

scheint aktuell wieder zurückzukommen....1,92$ aktuell!

[dw1z]

nur gewinnmitnahmen. ging die letzten tag ja ganzschön steil.
denkmal, dass es gegen börsenschluss wieder raufgeht

[ambestenreichheiraten]

was eine Achterbahnfahrt !

Ich glaube ich fang doch noch das traden an.... hätte sich bisher lohnen können

aber ich bleibe long &

[Pokerlui007]

Antwort auf Beitrag Nr.: 37.904.796 von ambestenreichheiraten am 02.09.09 18:47:46

bin dann ab morgen wieder dabei...

[Massel]

NEWS: 3 Personen angeblich mit H1N1 UND H5N1 Virus infiziert !

Wenn das wirklich zutreffen sollte , wirds jetzt gefährlich !


Co-transmission of H5N1 with Pandemic H1N1 in Egypt? Recombinomics Commentary 18:16
September 2, 2009


A 35 year-old Italian tourist is one of three people believed to have been infected with A(H1N1) virus, or swine flu, as well as the H5N1 virus, known as avian flu. The patients are recovering in the Egyptian Red Sea resort of Hurghada, said Mohammed Rifai, director general of preventive medicine.

Rifai also spoke of a 28-year-old man who tested positive for both viruses, after arriving at the port of Safaga after a pilgrimage to Saudi Arabia.

"We are waiting the results of the tests that have already been carried out in some patients suspected of having been infected by the H5N1 and the A(H1N1)," said World Health Organisation spokesman Gregory Hartl in an interview with Adnkronos Salute.

The above comments raise concerns of co-infections of pandemic H1N1 and H5N1, as well as human to human co-transmission. This development would create serious pandemic concerns.

The ability of the pandemic H1N1 to infected multiple species has been demonstrated by the widespread outbreaks in swine. Outbreaks in Canada have been reported in three provinces (Alberta, Quebec, and Manitoba) as well as two locations in Argentina near Buenos Aires, as well as three locations in Australia, These swine infections demonstrate the ease of transmission from humans to swine, as well as swine to swine. Recent results in Chile also demonstrated transmission to turkeys, raising concerns that H1N1 could be silently transmitting to multiple mammalian and avian species.

The jump to avian raised concerns that the H1N1 could interact with H5N1, which is predominantly found in birds, including long range migratory birds. Recent data also demonstrated H5N1 in pikas at Qinghai Lake, which is a mammalian reservoir.

Results from Egypt also raised concerns of co-infections because of the large number of mild H5N1 cases and the concentration in children. The heavy concentration in children raised concerns of silent spread of H5N1 in adults, providing opportunities for co-infection, which could lead to the H1N1 "rescuing" H5N1 leading to co-transmissions.

The presence of both viruses in multiple individuals identified over a brief time period suggests the viruses are efficiently co-transmitting, which creates serious concerns due to co-infections, or exchanges of genetic information via reassortment or recombination. Mammalian polymorphisms have been noted in prior H5N1 isolates, and pandemic H1N1 has H5N1 polymorphisms, indicating exchanges via recombination have happened previously.

However- co-infection and co-transmission would significantly increase the frequency and efficiency of recombination, which would be serious cause for concerns.

Confirmation that these three patients have co-infections of H5N1 and H1N1 (or swine and seasonal H1N1) would be useful

-----------------------------------------

gruß
massel

[Pokerlui007]

so bei 1,70$ bin ich wieder dabei...

[Pokerlui007]

wow was geht denn heute ab??!??

+25%!!

gut dass ich bei 1,50$ nochmal nachgelegt habe...

[aramis1]

UPDATE 1-AVI BioPharma gets funding to develop Junin virus drug
Mon Oct 5, 2009 8:50am EDT




Oct 5 (Reuters) - AVI BioPharma Inc (AVII.O) said it received expanded contract funding of about $11.5 million from the U.S. Department of Defense (DoD) to develop its drug candidate for the treatment of Junin virus infection, sending its shares up about 28 percent before the bell.

The funding will support development of the investigational new drug (IND) data package for its drug candidate, AVI-7012, to treat Junin virus infection, the company said.

Junin virus causes Argentine hemorrhagic fever and is transmitted to humans chiefly by rodents.

To date, the DoD has contracted with AVI for work potentially worth up to $45 million for the development of AVI's RNA-based drug candidates to treat Ebola, Marburg and Junin virus infections, the company said.

Shares of AVI were trading up at $1.99 before the bell. (Reporting by Jennifer Robin Raj in Bangalore; Editing by Vinu Pilakkott)

[dw1z]

wieso sind denn alle so ruhig geworden?

sprachlos, weil AVI so scheiße runt?

[Massel]

14.01.2010
Durststrecke überstanden

AVI scheint dir Durststrecke überstanden zu haben.

Chartbild hellt sich seit gestern schön auf.

Guter Anstieg bei hohem Volumen. (ohne News)

Desweiteren sollten bald Neuigkeiten (vielleicht auch schon unterwegs ?)

siehe :

http://www.avibio.com/duchenne_muscular_dystrophy.php

"In addition, AVI has now started the comprehensive series of preclinical tests necessary before a US study with AVI-4658 can be undertaken. The results from these studies will need to be reviewed by the FDA before a US study can start. It is hoped that the US study could start in early 2010."

Daher von mir ein "buy" mit Ziel 1.85 Euro

gruß
massel

[Massel]

Langsam kommt Bewegung in die Pipeline

Feb 05, 2010 08:00 ET
AVI BioPharma's Drug Candidate AVI-5038 Receives European Orphan Drug Designation for Duchenne Muscular Dystrophy

BOTHELL, WA--(Marketwire - February 5, 2010) - AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that it received an orphan drug designation from the Committee for Orphan Medical Products of the European Medicines Agency (EMEA) for AVI-5038, a drug candidate being developed by AVI for the treatment of Duchenne Muscular Dystrophy (DMD). DMD is a genetic muscle-wasting disease caused by failure to produce dystrophin. The orphan drug designation potentially may provide AVI up to 10 years of market exclusivity if the drug candidate is approved for marketing in the European Union (EU). AVI-4658, another drug being developed by AVI for DMD, received European orphan drug designation in 2008, and also potentially may receive up to 10 years of marketing exclusivity if approved in the EU.

"The EMEA's granting of orphan drug designation to AVI-5038 provides important regulatory support for our continuing commitment to develop disease modifying drugs for DMD patients," stated Dr. Leslie Hudson, President and CEO, AVI BioPharma, Inc. "We look forward to the opportunity to report continuing progress in our DMD program throughout the year, particularly with respect to our lead DMD drug candidate, AVI-4658, which is in an ongoing Phase 1b/2 clinical trial."

Products granted an orphan drug designation by the EMEA are intended for the diagnosis, prevention or treatment of life-threatening or chronically debilitating conditions that affect no more than five in 10,000 people in the EU, or are medicines which, for economic reasons, would unlikely be developed without incentives. The aim of the EU orphan medicines designation is to stimulate research and development of medicinal products for rare diseases by providing incentives to the pharmaceutical industry. This initiative helps to give patients suffering from rare diseases access to the same quality of treatment as other patients. Applications for designation of orphan medicines are reviewed by the EMEA through the Committee for Orphan Medicinal Products.

About Duchenne Muscular Dystrophy

DMD is one of the most common fatal genetic disorders to affect children around the world. Approximately one in every 3,500 boys worldwide is afflicted with DMD with 20,000 new cases reported each year. It is a devastating and incurable muscle-wasting disease associated with specific inborn errors in the gene that codes for dystrophin, a protein that plays a key structural role in muscle fiber function. Symptoms usually appear in male children by age three. Progressive muscle weakness of the legs and pelvis eventually spreads to the arms, neck, and other areas. By age 10, braces may be required for walking, and most patients are confined to a wheelchair by age 12. Eventually, this progresses to complete paralysis and increasing difficulty in breathing requiring ventilatory support. The condition is terminal and death usually occurs before the age of 30. The outpatient cost of care for a non-ambulatory DMD boy is among the highest of any disease. There is currently no cure for DMD, but for the first time ever, there are promising therapies in or moving into development.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy, including an ongoing systemic Phase 1b/2 clinical trial of exon skipping with AVI-4658. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as Junín, influenza, HCV or Dengue viruses. For more information, visit www.avibio.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: The statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties, including, but not limited to, the results of research and development efforts, the results of preclinical and clinical testing, the effect of regulation by the FDA and other agencies, the impact of competitive products, product development, commercialization and technological difficulties, and other risks detailed in the company's Securities and Exchange Commission filings.
Click here to see all recent news from this company
----------------------

gruß
massel

[homer65]

AVI BioPharma, Inc.
(NasdaqGM: AVII)

After Hours: 2.30 Up 0.67 (41.10%) 5:23PM EDT

290m gov contract

[Girolamo]

Hallo zusammen,

habe mal ein kleines Update zu AVII vorbereitet. Wen es interessiert...

AVI BioPharma ist ein Impfstoffforscher, dessen Ziel es ist, mittels seiner RNA-Technolgieplattform ein Präparat (Neugene) gegen Ebola und das Marburg-Virus zu entwickeln. Durch Tests wurde dabei festgestellt, dass der Wirkstoff von Neugene auch gegen verschiedene Grippestämme eingesetzt werden kann. Expertenkreise schrieben der RNA-Technologie die besten Chancen zu, sollte es zu einer Mutation des H1N1-Virus kommen. Unterstützt wurde die Tätigkeit von AVII immer wieder durch das US-Verteidigungsministerium, wobei immer wieder - verhältnismäßig kleine - Aufträge für die Entwicklung von Präparaten gegen mögliche terroristische Angriffe mit Biowaffen erteilt wurden.

Am 16.07.2010 gab AVII nun bekannt, dass es gelungen sei mit dem US-Verteidigungsministerium Verträge hinsichtlich der Entwicklung von Präparaten gegen das Ebola- und Marburg-Virus mit einem Gesamtvolumen von bis 291 Millionen USD auszuhandeln.

Bisher wird AVII bei 110.384.820 ausgegebenen Aktien - Stand: 21.05.2010 - und einem aktuellen Kurs von 1,99 USD mit gerademal ca. 220 Millionen USD bewertet, wobei die Firma zum 31.03.2010 noch über ein Cashpolster von über 41Millionen USD verfügte.

Quellen:

http://www.aktiencheck.de/artikel/analysen-Ausland-1929665.h…

http://investorrelations.avibio.com/...ng&cat=news&id=144974…

http://investorrelations.avibio.com/...&ID=1448508&highlight…

http://secfilings.nasdaq.com/...=10-Q&RcvdDate=5/10/2010&pdf…

http://secfilings.nasdaq.com/...0-K/A&RcvdDate=5/24/2010&pdf…

[Girolamo]

Die 2-USD-Marke wurde gestern auch auf Schlusskursbasis geknackt. Mal schauen, ob wir diese auch dauerhaft hinter uns lassen können...

[Girolamo]

Antwort auf Beitrag Nr.: 39.962.980 von Girolamo am 11.08.10 07:33:01

Im schwachen Marktumfeld haben wir nach einem kurzen Zwischenspurt bis 2,13 USD am Ende die 2 USD doch wieder gerissen und sind bei 1,99 USD gelandet...

[dw1z]

guckt man mal ein bisschen auf die chartechnik sieh es doch nach einem gesunden aufwärtsrend aus =)

freu mich das endlich mal wieder ein bisschen bewegung reinkommt

[Girolamo]

Antwort auf Beitrag Nr.: 40.001.607 von dw1z am 17.08.10 23:02:32

NEWS!

Das Medikament gegen das Ebola- und Marburg-Virus darf nun am Menschen getestet werden.

http://investorrelations.avibio.com/phoenix.zhtml?c=64231&p=…

Zum besseren Verständnis ein deutscher Beitrag:

"USA

Ebola-Medikament für Menschenversuche freigegeben
23. August 2010, 14:22


Ein wichtiger Schritt zur Bekämpfung des Ebola-Virus ist gelungen.

US-Behörde gibt grünes Licht: Bei Affen hatte die Behandlung hohe Erfolgsraten erzielt

Frederick/Bothell - Die U.S. Food and Drug Administration hat Wissenschaftern des US Army Medical Research Institute of Infectious Diseases und des Pharmaunternehmens AVI BioPharma erlaubt, ein Medikament gegen Ebola an Menschen zu testen. Zuvor konnte der Beweis erbracht werden, dass das Präparat bei Affen wirksam ist - nun wurden erste Tests an einer kleinen Gruppe von Freiwilligen genehmigt.

Das Mittel enthält Nukleinsäuren, die zu denen im Erbmaterial des Ebola-Virus komplementär sind und dadurch die Vermehrung des Virus so lange blockieren, bis die Immunabwehr die ursprünglich eingedrungenen Viren eliminieren kann. Die Affen-Tests hatten eine 60-prozentige Heilungsquote erbracht; im Einsatz gegen das nahe mit Ebola verwandte Marburg-Virus berichten die Forscher sogar von einer 100-prozentigen Heilungsquote. Die Sterblichkeitsrate beim Menschen liegt - abhängig davon, um welchen Stamm von Ebolaviren es sich handelt - zwischen 50 und 90 Prozent. Bei Affen kann die Letalitätsrate sogar an die 100 Prozent gehen.

Seit das Virus 1976 entdeckt wurde, wurden etwa 1.200 Todesfälle registriert. Ebola ist in verschiedenen Kontexten von Bedeutung: In erster Linie natürlich für die Menschen in Zentralafrika, wo es in Abständen von einigen Jahren immer wieder zu Ebola-Ausbrüchen kommt. Biologen sehen in dem Virus zudem eine Gefahr für die dortigen ohnehin stark bedrohten Menschaffen-Populationen, da das Virus auch sie befällt. In den USA wiederum gibt es Befürchtungen, dass das Virus von Terroristen als biologischer Kampfstoff eingesetzt werden könnte. Aus diesem Grund wurden nach den Anschlägen vom 11. September 2001 die Ebola-Forschung intensiviert und die finanziellen Mittel aufgestockt. (red/pte)"

http://derstandard.at/1282273393307/USA-Ebola-Medikament-fue…

[Girolamo]

Die nächste "Schweinegrippewelle" kann kommen. Zumindest aus Sicht von AVI...

AVI BioPharma Announces Positive Results Against Human Pandemic H1N1 Influenza Virus in Preclinical Studies of AVI-7100

AVI-7100 Demonstrates Statistically Significant Activity Versus Saline and Tamiflu(R) Controls, Up to 3.9 Log Greater Reduction in Average Viral Titer AVI BioPharma and US Department of Defense Conduct Successful Rapid Response Exercise Against Real-World Threat, Pandemic H1N1 Virus

BOTHELL, WA, Aug 24, 2010 (MARKETWIRE via COMTEX) --

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced positive results from two preclinical studies evaluating the therapeutic potential of AVI-7100 against a fully virulent pandemic H1N1 virus, also known as swine flu or swine origin influenza virus. An analysis of the data from the studies demonstrated statistically significant reductions in average viral titer versus a saline control and a control with Tamiflu(R), a standard of care drug. The studies of AVI-7100, which used AVI's proprietary PMOplus(TM) chemistry, were supported by the Transformational Medical Technologies program (TMT) of the U.S. Department of Defense to identify RNA-based drug candidates against pandemic H1N1 virus. The studies were undertaken as part of a rapid response exercise demonstrating TMT's ability, in partnership with AVI, to rapidly respond to a real-world emerging viral threat.

"These H1N1 results build on the significant success we've had applying our RNA-based technologies and advanced proprietary chemistries, such as PMOplus(TM), to anti-infective therapeutic candidates," said J. David Boyle II, interim President and CEO of AVI BioPharma. "Based on these results, TMT continues to support AVI-7100, funding an accelerated IND enabling program and Phase 1 study, as well as expanded preclinical evaluation that explores AVI-7100's potential as a broad spectrum influenza therapeutic. We look forward to continuing to work closely with TMT to support our national preparedness against biological threats."

Study Results An analysis of the results from the two preclinical studies evaluating AVI-7100 against a fully virulent strain of pandemic H1N1 virus in a ferret model demonstrated potent, statistically significant reductions in the average viral titer in the upper respiratory region versus saline and Tamiflu controls. In the analysis of these two studies, AVI-7100 administered intraperitoneally at 10 mg/kg resulted in statistically significant reductions in the combined daily average viral titer through peak viral load (days 1-3) versus saline control (p=0.0012) and Tamiflu control (p=0.0103) by up to 3.9 log. Maximum reductions in the cumulative average viral titer of 5.1 log versus saline control and 4.52 log versus Tamiflu control were observed through day 5, but statistical analysis at this time point was not possible due to limited animal numbers.

Microscopic examination of the lungs of the infected ferrets seven days after infection evaluated the extent of regional tissue damage. Pathology scores in each study revealed only mild damage in the AVI-7100 treated ferrets versus severe damage in both saline controls and Tamiflu controls. The gross examination of the lung and spleens of the AVI-7100 treated ferrets appear normal, but obvious damage was observed in these tissues in the saline and Tamiflu controls. Finally, the number of infiltrating macrophages in the bronchiolar space was reduced in the AVI-7100 treated ferrets compared to the saline or the Tamiflu controls.

Presentation of the final data from these studies is planned for a medical conference in 2010.

About The TMT/AVI H1N1 Rapid Response Exercise As part of its ongoing evaluation of programs being conducted in cooperation with AVI, the U.S. Department of Defense Transformational Medical Technologies program established a contract with AVI to conduct a rapid response exercise against a real-world emerging threat, the pandemic H1N1 virus. The intent of the exercise was to demonstrate the capability of AVI to efficiently respond to a real-world emerging viral threat by rapidly designing and producing multiple therapeutic candidates and evaluating preclinical efficacy.

Initially the exercise involved identifying target sequences against H1N1, designing several drug candidates utilizing proprietary derivatives of AVI's antisense phosphorodiamidate morpholino oligomers (PMO) chemistry, and then manufacturing the candidates in sufficient quantity for preclinical testing. This was successfully accomplished in approximately one week, demonstrating AVI's ability to rapidly respond to a real-world viral threat utilizing the AVI's RNA based therapeutics platform.
Subsequently, AVI evaluated its RNA-based drug candidates in preclinical studies using a mouse model of seasonal flu and identified two lead candidates, including AVI-7100. The two lead candidates were tested in the more advanced ferret model utilizing a fully virulent human pandemic H1N1 virus. The ferret studies included various treatment groups employing the lead candidates administered via intraperitoneal and intranasal dosing routes, a saline control group, a scrambled RNA sequence control group and a control group dosed with Tamiflu, a standard of care drug. While both lead candidates and routes of administration were indicative of activity versus all controls, AVI-7100 administered intraperitoneally demonstrated overall superiority.

About AVI-7100 AVI-7100 employs AVI's patented PMOplus(TM) technology that selectively introduces positive charges to its phosphordiamidate morpholino oligomer (PMO) backbone to improve selective interaction between the drug and its target. The PMOplus(TM) chemistry platform previously generated two Investigational New Drugs (INDs) for AVI-6002 and AVI-6003, AVI's lead hemorrhagic fever virus therapeutic candidates for Ebola and Marburg viruses, respectively. These hemorrhagic fever virus therapeutic candidates are being developed under a July 2010 contract awarded through the U.S. Department of Defense Transformational Medical Technologies program (TMT). This contract provides funding to AVI of up to approximately $291 million.

Activities to develop AVI-7100 as a medical countermeasure against the pandemic H1N1 influenza virus are being funded under a June 2010 contract awarded to AVI through the TMT program. The contract provides for funding of up to $18 million to advance the development of AVI-7100, and includes studies enabling an Investigational New Drug (IND) application with the U.S. Food and Drug Administration, the study of an intranasal delivery formulation, and the funding of a Phase 1 clinical trial to obtain human safety data to support potential use under an Emergency Use Authorization.

Additional funding under an earlier contract awarded to AVI via the TMT program is supporting continued preclinical evaluation of AVI-7100 against H1N1 as well as expanded preclinical evaluation against H5N1 (avian flu) and drug resistant H1N1 and H3N2 flu strains. Funding from this earlier contract also supported the rapid response exercise and is valued at up to $8.1 million.

About Pandemic H1N1 Influenza On June 11, 2009 the World Health Organization declared a pandemic of H1N1 influenza. The virus was first detected in people in the U.S. in April 2009 and was referred to as "swine flu" because many of the genes in the virus were very similar to those found in flu viruses that circulate in pigs (swine). Illness with the 2009 H1N1 virus has ranged from mild to severe. Symptoms include fever, cough, runny nose, headache, chills and fatigue. Many people infected with H1N1 also have respiratory symptoms without a fever. Severe illness and deaths have occurred as a result of illness associated with the virus. The Centers for Disease Control and Prevention (CDC) estimated that between April 2009 and April 2010 there were up to 89 million cases of H1N1 infection in the U.S. The CDC also estimated that there were up to 403,000 H1N1-related hospitalizations in the U.S. during the same time period.

About the Defense Threat Reduction Agency The Defense Threat Reduction Agency (DTRA) was founded in 1998 to integrate and focus the capabilities of the Department of Defense (DoD) that address the threat by weapons of mass destruction (WMD). DTRA's mission is to safeguard the United States and its allies from chemical, biological, radiological, nuclear and high-yield explosive WMDs by providing capabilities to reduce, eliminate and count the threat and mitigate its effects. DTRA combines DoD resources, expertise, and capabilities to ensure the United States remains ready and able to address the present and future WMD threats. For more information on DTRA, visit www.dtra.mil.
About the Transformational Medical Technologies Program (TMT) The TMT program was created by the U.S. Department of Defense to protect the Warfighter from emerging and genetically altered biological threats by discovering and developing a wide range of medical countermeasures through enhanced medical research, development, test and evaluation programs. The TMT Program Office is matrixed from the Joint Science and Technology Office -- DTRA and Joint Program Executive Office -- Chemical and Biological Defense, with oversight from the Office of the Secretary of Defense. For more information on TMT, visit http://www.tmti-cbdefense.org.

About AVI BioPharma AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, our technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging our highly differentiated RNA antisense-based technology platform, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses. For more information, visit www.avibio.com.

Forward-Looking Statements and Information

This press release contains statements that are forward-looking, including statements about the amount and timing of potential funding; the development of AVI 7100, AVI 6002 and AVI 6003, including preclinical development, filing of an IND application, completion of a Phase 1 human safety clinical trial, clinical development and FDA approval; AVI's PMOplus(TM) chemistry and other antisense-based technology and its ability to protect against the H1N1 virus, as well as its efficacy, potency and utility in the treatment of infectious diseases, and its potential to treat a broad number of human diseases. These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control. Known risk factors include, among others: development of any of AVI 7100 , AVI 6002 and/or AVI 6003 may not result in funding from the TMT in the anticipated amounts or on a timely basis, if at all; clinical trials may not demonstrate safety and efficacy of any of our drug candidates and/or our antisense-based technology platform; any of our drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable. The results and analysis of the AVI 7100 studies described in this press release are subject to interpretation, and may not be repeated in later preclinical and clinical trials. The AVI 7100 study described in this press release is subject to interpretation and included small numbers of animal subjects which may limit the utility of the statistical analysis conducted in predicting future results. Further, the AVI 7100 study results described in this press release is not predictive of future outcomes and may not be repeated in later preclinical and clinical trials.

SOURCE: AVI BioPharma, Inc.

http://investorrelations.avibio.com/phoenix.zhtml?c=64231&p=…

[Girolamo]

Antwort auf Beitrag Nr.: 40.038.316 von Girolamo am 24.08.10 19:37:41

NEWS OUT:

AVI BioPharma Issued U.S. Patent Providing Key Coverage of RNA-Based Therapeutics as Antibacterial Agents

BOTHELL, WA, Sep 08, 2010 (MARKETWIRE via COMTEX) --

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, announced today that the United States Patent and Trademark Office issued AVI a patent granting key claims covering the use of phosphorodiamidate morpholino based oligomers (PMOs) as antibacterial agents. The patent, titled Antisense Antibacterial Method and Compound (No. 7,790,694), contains broad claims for the use of peptide-conjugated phosphorodiamidate morpholino oligomers (PPMOs) to target the acyl carrier protein (AcpP), a gene considered essential for bacterial growth in both gram positive and gram negative bacteria.

"This patent represents an important addition to our intellectual property estate and further demonstrates the innovation and therapeutic potential of our unique RNA-based technology in the development of a new class of anti-infective agents," said J. David Boyle II, interim President and CEO of AVI BioPharma. "We believe that RNA-based therapeutics employing our advanced PMO chemistries can become an important new category of antibacterial agents. Instead of directly targeting proteins like most traditional antibiotics, our PMO-based compounds target key microbial RNAs to inhibit protein expression at the gene translation level. By leveraging our differentiated capabilities, AVI plans to rapidly advance novel antibacterial candidates in this increasingly important therapeutic area."

AcpP is an important component in the synthesis of fatty acids necessary for bacterial growth. Data from several in vitro and in vivo pre-clinical studies performed by AVI across multiple bacterial species demonstrate the potential breadth of AVI's antibacterial platform. AVI recently published data, accompanied by a related editorial commentary in the Journal of Infectious Diseases describing positive preclinical results from studies utilizing an AVI oligomer targeting AcpP against Burkholderia cepacia complex.

Preclinical studies performed by AVI and collaborators using its PMO-based compounds have provided encouraging data against gram positive and negative bacteria, which includes Burkholderia cepacia as well as E. coli, Bacillus anthracis, Mycobacterium and Salmonella. In in vitro studies, AVI's compounds have demonstrated bactericidal activity against both antibiotic susceptible and resistant bacteria, and to date have not shown cross-resistance to other classes of antibiotics.

About AVI's Advanced Phosphorodiamidate Morpholino Oligomer Chemistries

The core PMO-based chemistry was originally pioneered by AVI and provides a unique and versatile platform for developing advanced chemistries to support the development of a range of therapeutic candidates that target different types of RNA.

Advanced generation PMO-based antisense chemistries with potentially superior drug-like performance characteristics have been developed by AVI and are being applied to the discovery and development of new therapeutic candidates. AVI's advanced chemistries include the PPMO, PMOplus(TM) and PMO-X, each of which provides potential improvements to various drug-like characteristics to therapeutic candidates, such as potency, bioavailability, therapeutic index and tissue selectivity. AVI continues to research additional chemistry advances to further optimize its core proprietary technology platforms as well as to develop further novel analogues that could provide additional improvement to a range of beneficial characteristics, including the above.

About AVI BioPharma

AVI BioPharma is focused on the discovery and development of novel RNA-based therapeutics for rare and infectious diseases, as well as other select disease targets. Applying pioneering technologies developed and optimized by AVI, we are able to target a broad range of diseases and disorders through distinct RNA-based mechanisms of action. Unlike other RNA-based approaches, our technologies can be used to directly target both messenger RNA (mRNA) and precursor messenger RNA (pre-mRNA) to either down-regulate (inhibit) or up-regulate (promote) the expression of targeted genes or proteins. By leveraging our highly differentiated RNA antisense-based technology platform, we have built a pipeline of potentially transformative therapeutic agents, including a clinical stage Duchenne muscular dystrophy candidate and anti-infective candidates for influenza and hemorrhagic fever viruses. For more information, visit www.avibio.com.

Forward-Looking Statements and Information

This press release contains statements that are forward-looking, including statements about AVI's PPMO, PMOplus(TM) and PMO-X chemistries and other antisense-based technology and their efficacy, potency and utility in the treatment of infectious diseases, and their potential to treat a broad number of human diseases. These forward-looking statements involve risks and uncertainties, many of which are beyond AVI's control, including that preclinical and clinical trials may not demonstrate safety and efficacy of any of our drug candidates and/or our antisense-based technology platform, and any of our drug candidates may fail in development, may not receive required regulatory approvals, or be delayed to a point where they do not become commercially viable. Further, the results described in this press release are not predictive of future outcomes and may not be repeated in later preclinical and clinical trials.

SOURCE: AVI BioPharma, Inc.

http://investorrelations.avibio.com/phoenix.zhtml?c=64231&p=…